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ABSTRACT 
 
Maile Anne Henson:  Role of the NMDA receptor subunit, NR3A, in glutamatergic 
synapse development 
(Under the direction of Benjamin D. Philpot, Ph.D.)
 
 
Proper functioning of neuronal networks relies on the refinement of immature synaptic 
contacts, although many aspects of this process are poorly understood.  NMDA-type 
glutamate receptors (NMDARs) are crucial mediators of brain development and function, 
especially excitatory synapse development.  Accumulating evidence suggests that the 
NR3A subtype of NMDARs has an unappreciated and particularly important role during 
early postnatal development.  These developmentally regulated receptor subunits serve a 
prominent role in CNS development soon after birth, and their role is likely less 
important prenatally and in adulthood.  Inclusion of the nonconventional NR3A subunit 
in NMDARs may serve to alter cortical microcircuitry in the brain anatomically, through 
reduced numbers of dendritic spines, and functionally, through weakened synaptic 
connections due to decreased glutamatergic neurotransmission and calcium influx 
through NMDARs.  In this dissertation, using molecular and biochemical techniques in 
human and mouse model systems, I explored (1) how developmental changes in the 
complement of glutamate receptors, specifically NR3A subunits, enable synapses to 
mature or to be eliminated in the mouse forebrain, and (2) whether an increase in NR3A 
subunit expression could provide an endogenous basis for the NMDAR hypofunction 
observed in schizophrenia.  Because the profound effects that NR3A is likely to have on 
 iv
synapse development have not been fully considered, my research addresses this gap in 
our knowledge.  Dissecting the contributions of specific NMDAR subunits to synapse 
development will increase our understanding of the maturation of forebrain circuitry and 
its effects on learning and memory processes, as well as guide therapeutic strategies for 
treating pathologies associated with NMDAR dysfunction, such as schizophrenia.
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PREFACE 
 
In my graduate training, I sought to explore the molecular mechanisms of 
synaptic development and function in the healthy and diseased brain.  My aim was to 
receive a broad range of training in cellular and molecular neuroscience, scientific 
writing, and critical evaluation of experimental design and analysis.  In the Philpot Lab, I 
gravitated towards the molecular side of neurobiology, studying the role of NMDA-type 
glutamate receptors (NMDARs) in synaptic development. Because glutamate receptors 
are critical for synaptic plasticity and neuronal cell death, understanding their function 
has relevance for neurological conditions, such as schizophrenia, stroke, and 
neurodegenerative diseases.   My work explored the contributions of NMDAR subunits 
to the strengthening and weakening of connections during excitatory synapse 
development, and may shed light on the mechanisms for glutamate receptor dysfunction 
seen in schizophrenia.  These studies have opened up questions about glutamate receptor 
trafficking in synapse assembly and elimination, especially as they relate to 
neurodevelopmental disorders such as schizophrenia, and have helped me to gain a 
deeper understanding of the relationship between synaptic formation and abnormal 
development of neuronal microcircuits. 
 My initial project in the lab involved using RNA interference (RNAi)-mediated 
gene silencing to provide temporal and regional control for modifying NMDAR subunits 
in the neocortex.  By selectively knocking down expression of NMDAR subunit, NR2A, 
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in cortical neurons both in vitro and in vivo, I was able to produce encouraging 
preliminary data demonstrating the powerful potential of cell-penetrating peptides for 
RNAi delivery.  This technology may be useful in future projects requiring a method to 
selectively downregulate NMDAR subunits, and thus parse NMDAR subtype-specific 
roles in cortical development. 
I then turned to examining the role of the novel NMDAR subunit, NR3A, in the 
neurodevelopmental disorder, schizophrenia.  Behavioral problems occurring in 
schizophrenics are thought to arise from aberrant development, stabilization, and 
plasticity of synapses in the prefrontal cortex.  Several lines of evidence suggest that 
hypofunction of the NMDAR may play a particularly important role in the underlying 
pathophysiology, although the molecular basis for this is still unknown.  Because the 
NR3A subunit acts in a dominant-negative fashion to reduce NMDAR function, I 
hypothesized that while transient expression of NR3A is important for brain 
development, the persistent expression of NR3A might contribute to disease states.  
Indeed, increased NR3A expression in schizophrenia could be an endogenous mechanism 
and account for the observed NMDAR hypofunction and improper formation of cortical 
circuits in this disease.  My data resulted in a first-author manuscript in Cerebral Cortex, 
detailing the novel findings of NR3A expression during human development and in 
schizophrenic postmortem human tissue. 
Because the developmental profiles of NR3A showed strong parallels between 
humans, non-human primates, and rodents, this gave me confidence in the relevance of 
NR3A expression across mammalian species.  My focus then shifted to using mice to 
model the consequences of NR3A loss and overexpression in synapse development in a 
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controlled environment, without confounding variables found in humans such as 
medication history.  The goal was to carefully characterize the synaptic presence of 
NR3A. Two pressing issues were (1) to define the subcellular localization of NR3A-
containing receptors at peak expression levels, and (2) to determine whether the influence 
of NR3A is to serve as a ‘synaptic brake’ to limit synapse/spine formation or to act as a 
‘synaptic marker’ to promote those processes. These two hypotheses are not mutually 
exclusive.  The data from these experiments are still being analyzed, but they suggest that 
NR3A acts as a molecular brake to negatively regulate expression of several key synaptic 
proteins in the maturation of excitatory synapses. 
 Portions of this work have been previously published or are in preparation for 
publication:  
 
CHAPTERS 1 and 4 
 Henson, M.A.*, Roberts, A.C.*, Perez-Otano, I., and Philpot, B.D. (in press).  
 Influence of NR3A in NMDA receptor functions.  Progress in Neurobiology.  
 
CHAPTER 2 
 Henson, M.A., Roberts, A.C., Salimi, K, Vadlamudi, S, Hamer, R.M., Gilmore, 
 J.H., Jarskog, L.F., Philpot, B.D. (2008).  Developmental regulation of the 
 NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex.  Cerebral 
 Cortex 18:2560-2573. 
 
CHAPTER 3 
 Roberts, A.C., Diez-Garcia, J., Rodriguiz, R.M., Lopez, I.P., Lujan, R., Martinez-
 Turrillas, R., Pico, E., Henson, M.A., Bernardo, D.R., Jarrett, T.M., Clendeninn, 
 D.J., Lopez-Mascaraque, L., Feng, G., Lo, D.C., Wesseling, J.F., Wetsel, W.C., 
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CHAPTER 1 
 
Introduction and Background 
 
 
Synapses form the basis for neuronal communication 
 
The fundamental unit for information processing in the brain is the synapse.  The 
establishment of a functional synapse that provides reliable glutamate neurotransmission 
requires the participation of pre- and postsynaptic elements that are stabilized through 
coordinated activity (Katz and Shatz, 1996).  In early brain development, synaptogenesis 
results in a massive overproduction of synapses and the subsequent culling of weak, 
uncoordinated processes (Hua and Smith, 2004).  The remaining synaptic junctions 
undergo structural and molecular maturation of the postsynaptic spines.  
 
Developing synapses undergo alterations in spine/synapse size, receptor 
complement, synaptic activity, and synaptic plasticity 
 
Nascent excitatory synapses undergo remarkable transformations in spine 
morphology, the composition and numbers of glutamate receptors, and the ability to 
undergo activity-driven synaptic plasticity mechanisms that lead to strengthening or 
weakening of connections.  Immature dendritic spines are small, thin structures which 
grow in size into full, mushroom-shaped heads that are capable of supporting increasing 
demands of the mature synapse (Matsuzaki et al., 2001).  Other changes include the 
stabilizing and clustering of membrane receptors by scaffolding/anchoring proteins of the 
postsynaptic density (PSD), and enabling lifelong potentiation of the synapse 
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(Matsuzaki et al., 2004).    However, when threshold activity levels are not reached and 
synapses are not strengthened and stabilized, weakened synapses no longer can support 
neurotransmission and may become depressed and eliminated (Zhou et al., 2004; 
Bastrikova et al., 2008; Becker et al., 2008). 
 NMDAR activation is required for synapse maturation and, because its subunits 
impart different properties to the receptor (Cull-Candy and Leszkiewicz, 2004; Paoletti 
and Neyton, 2007), the transition between ‘immature’ and ‘mature’ forms of NMDARs is 
thought to regulate the stabilization of NMDARs in the PSD and the subsequent decline 
in plasticity of the synapse (Burgard and Hablitz, 1994).  Immature synapses are 
characterized by the presence of predominantly NR2B-containing NMDARs, which are 
replaced with the more stable subtype, NR2A (Philpot et al., 2001a; Barria and Malinow, 
2002; Bellone and Nicoll, 2007).  Importantly, the upregulation of NR2A is accompanied 
by the synaptic incorporation of AMPARs that are required to respond to increased 
neuronal activity from the presynaptic terminal.  This is crucial because most immature 
synapses do not contain AMPARs, only NMDARs (Isaac et al., 1995; Liao et al., 1995; 
Rumpel et al., 1998; Shi et al., 1999).  Because AMPARs are responsible for the majority 
of excitatory neurotransmission, these electrically ‘silent’ synapses have functional 
consequences in early brain development that have only begun to be addressed. 
Synapse stabilization is driven by sensory experience.  NMDAR-dependent 
synaptic plasticity is a remarkable phenomenon whereby synapses can rapidly alter the 
efficiency with which they convey information from one neuron to another, resulting in 
their strengthening or weakening.  Strong or weak electrical activity between neurons 
results in the induction of long-term potentiation (LTP) and long-term depression (LTD), 
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respectively (Malenka and Bear, 2004).  Both processes depend upon coincident 
activation of NMDARs by glutamate binding and membrane depolarization, which 
permits low and high levels of calcium influx, respectively, and the rapid insertion or 
removal of AMPARs.  
 
The N-methyl-D-aspartate type glutamate receptor (NMDAR) 
 
 NMDARs are activated by glutamate, the most common excitatory 
neurotransmitter in the central nervous system, and are essential for the proper 
development of cortical circuitry and synaptic function (McBain and Mayer, 1994; Cull-
Candy et al., 2001; Perez-Otano and Ehlers, 2004; Lau and Zukin, 2007).  Dysfunction of 
NMDARs has been implicated in a variety of pathological conditions including 
schizophrenia (Mueller and Meador-Woodruff, 2004), neurodegenerative disease 
(Bonuccelli and Del Dotto, 2006; Wenk, 2006; Fan and Raymond, 2007), stroke (Martin 
et al., 1998), white-matter injury (Karadottir et al., 2005; Salter and Fern, 2005; Micu et 
al., 2006), and neuropathic pain (Dubner and Ruda, 1992). 
 Great diversity exists in NMDAR subtypes.  The NMDAR is thought to be a 
tetrameric transmembrane channel (Laube et al., 1998; Rosenmund et al., 1998; Ulbrich 
and Isacoff, 2007) composed of combinations of the obligatory NR1 subunit with NR2 
and/or NR3 subunits (Schorge and Colquhoun, 2003; Furukawa et al., 2005).  The NR1 
subunit exists as eight functional splice variants (Durand et al., 1992; Sugihara et al., 
1992; Durand et al., 1993; Hollmann et al., 1993; Mori and Mishina, 1995), while 
separate genes produce four types of NR2 (NR2A-D) and two types of NR3 (NR3A-B) 
subunits (Moriyoshi et al., 1991; Meguro et al., 1992; Monyer et al., 1992; Mishina et al., 
1993; Ciabarra et al., 1995; Sucher et al., 1995; Nishi et al., 2001).  Each receptor 
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subtype exhibits temporal and regional specificity (Monyer et al., 1994; Sheng et al., 
1994) and unique functional properties (Monyer et al., 1994; Paoletti and Neyton, 2007)  
which are determined by the specific combination of subunits assembled to form the 
heteromer.  For instance, subunit composition determines receptor properties such as 
glutamate affinity, receptor desensitization, and pharmacological sensitivity (Cull-Candy 
and Leszkiewicz, 2004; Paoletti and Neyton, 2007).  A major goal in neuroscience is to 
characterize the contributions of individual subunit types to NMDAR function.  Such 
knowledge will increase our understanding of how NMDARs contribute to normal brain 
development, as well as guide therapeutic strategies for treating pathologies associated 
with NMDAR dysfunction.   
 While attention has focused on the role of NR2 subunits in neural function, much 
less is known about how the more recently identified NR3 subunits, NR3A and NR3B, 
modify NMDAR functions.  This is surprising, given that NR3 subunits act in a novel, 
dominant-negative manner to suppress NMDAR activity (Ciabarra et al., 1995; Sucher et 
al., 1995; Nishi et al., 2001; Matsuda et al., 2002).  Interest in NR3A has grown with the 
observations that the subunit influences dendritic spine density (Das et al., 1998; Roberts 
et al., 2009), synapse maturation (Roberts et al., 2009), memory consolidation (Roberts et 
al., 2009), cell survival (Nakanishi et al., 2009), and may be involved in certain 
neuropathologies (Zhang et al., 2002; Mueller and Meador-Woodruff, 2004; Karadottir et 
al., 2005; Salter and Fern, 2005; Micu et al., 2006). 
 Although NR3A was identified over a decade ago, there have been few efforts to 
consolidate knowledge of its functions and possible disease roles (although see (Eriksson 
et al., 2007b; Cavara and Hollmann, 2008).  Given the large number of disorders 
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associated with NMDAR dysfunction, and the paucity of studies that have examined the 
putative contribution of NR3 subtypes, we anticipate that its unique structure, expression 
patterns, and function will make it an important therapeutic target.   
 
NR3A amino acid sequence and structure 
 
 NR3A was identified through sequence and structure homology to other GRIN 
(Glutamate Receptor Ionotropic N-methyl-D-aspartate) genes, and originally termed ‘-
1’ or ‘NMDAR-like’ (NMDAR-L) (Ciabarra et al., 1995; Sucher et al., 1995).  The 
GRIN3A gene localizes to human chromosome 9q34.1, and consists of 9 exons spanning 
1115 amino acids (Andersson et al., 2001) (Figure 1.1).  The high level of sequence 
homology between human and rodent NR3A (93%) indicates that its function is likely 
similar between mammalian species (Andersson et al., 2001; Eriksson et al., 2002).  Most 
consensus sites are conserved between rodents and humans, although the lack of gene 
equivalents in D. melanogaster and C. elegans suggests that evolutionary changes may 
have necessitated the emergence of NR3 subtypes in vertebrates (Matsuda et al., 2002).  
By sequence alignment, NR3A shares the greatest homology with NR3B (GRIN3B; 
57%), having low identity with NR1 (27%) and NR2 subunits (24-29%) as well as non-
NMDA glutamate receptors (23%) (Andersson et al., 2001). 
 NR3A shares structural features with other ionotropic glutamate receptor subunits 
(Figure 1.2), including a 4-pass transmembrane topology which forms the channel pore, 
a large extracellular N-terminal ligand-binding domain with a putative signal peptide and 
multiple glycosylation consensus sites, and a cytoplasmic tail.  Like other NMDAR 
subunits, the intracellular C-terminus of NR3A contains sites potentially phosphorylated 
by protein kinases A and C (PKA, PKC), protein tyrosine kinase (PTK), and 
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calcium/calmodulin-dependent kinase II (CaMKII) (Ciabarra et al., 1995; Sucher et al., 
1995; Andersson et al., 2001; Nishi et al., 2001; Eriksson et al., 2002), suggesting that 
phosphorylation could play critical roles in regulating NR3A trafficking, signaling, and 
channel properties (Chen and Roche, 2007).  NR3A also contains a motif with two 
vicinal cysteine residues, CC(Y/K)G(Y/F)CID(I/L)L, required for redox modulation 
(Sullivan et al., 1994; Sucher et al., 1995; Andersson et al., 2001), as well as an 
intracellular RXR motif which may serve as an endoplasmic reticulum (ER) retention 
signal (Perez-Otano et al., 2001).   
Despite similarities to other NMDAR subunits, NR3A exhibits a number of 
distinctive features.  As with other NMDAR subunits, the NR3A amino acid sequence 
encodes an extracellular bi-lobed domain (split into S1 and S2 segments by membrane 
domains TM1, TM2, and TM3) that determines ligand binding specificity.  But unlike 
NR2 subunits, which bind glutamate, the S1 region of the extracellular N-terminus and 
the S2 region of the extracellular loop between TM3 and TM4 form a glycine binding 
pocket, a clamshell-like structure (Paas, 1998; Yao and Mayer, 2006; Yao et al., 2008).  
Additionally, the second membrane pore loop (TM2) and the third membrane pore loop 
(TM3) in both NR3A and NR3B are substantially different from other NMDAR subunits.  
In NR1/NR2 NMDARs, an ion selectivity filter at TM2 is formed by an interaction 
between asparagine (N) residues of NR1 (N-site) and NR2 subunits (N+1 site) (Kuner et 
al., 1996).  In NR3A subunits, however, the N-site is replaced by a glycine (G) (Sucher et 
al., 1995; Nishi et al., 2001; Matsuda et al., 2002), and this residue apparently has little 
influence upon ion selectivity (Wada et al., 2006).  While NR3A-containing NMDARs 
apparently lack the N and N+1 site selectivity filter, they appear to have a novel 
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construction of the outer vestibule that can influence ionic currents.  Unlike NR1/NR2 
NMDARs, the TM3 domain between NR1 and NR3A subunits has a symmetrical 
configuration that forms a ring of threonines.  This ring constricts the external vestibule 
and may account for the observed reductions in Ca
2+
 permeability, ionic currents, and 
magnesium (Mg
2+
) sensitivity of NR3A-containing NMDARs (Wada et al., 2006).  
Another distinct characteristic is that the C-termini of NR3A and NR3B lack consensus 
sequences for PDZ domain protein-binding (Matsuda et al., 2002; Eriksson et al., 2007b), 
prominent features of other glutamate receptor subunits that permit stable anchoring to 
the postsynaptic density.  Finally, with a calculated molecular weight of ~125kD, NR3A 
is the most heavily glycosylated glutamate receptor subunit (Ciabarra and Sevarino, 
1997).  The functional significance of this robust glycosylation is unclear, but it may alter 
channel gating kinetics (Covarrubias et al., 1989; Chazot et al., 1995). 
Alternative mRNA splicing is another means to modify NR3A functions.  A 60-
base pair insert encoding an additional 20 amino acid sequence at the intracellular C-
terminus has been described in rodents, resulting in short (NR3A-s or NR3A-1) and long 
(NR3A-l or NR3A-2) forms of NR3A (Sun et al., 1998; Eriksson et al., 2002; Sasaki et 
al., 2002)(Figures 1.1 and 1.2).  The long splice variant NR3A-l, which contains putative 
PKA, PKC, and CaMKII phosphorylation sites, is apparently lacking in human NR3A 
(Andersson et al., 2001; Eriksson et al., 2002).   
 
Developmental and regional expression 
 NR3A levels change dramatically over development and exhibit a unique 
spatiotemporal expression pattern when compared to other NMDAR subunits.  While 
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NR3A expression is grossly similar across mammalian species, there are some notable 
differences.  Understanding these distribution patterns will help predict how prospective 
NR3A agonists and antagonists are likely to affect neural function.  Because the existing 
data on NR3A expression patterns are sometimes contradictory, the information is 
summarized here in tabular format to present an overview of the consensus findings from 
brain tissue (Table 1.1). 
 
Ontogenetic profiles 
 Overall, NR3A expression is low embryonically, peaks during early postnatal life, 
and diminishes to much lower levels in adulthood.  This expression profile is observed in 
many regions of the brain and in different species (Table 1.1), suggesting that it may play 
a specific role during postnatal neural development amongst mammals (Ciabarra et al., 
1995; Sucher et al., 1995; Das et al., 1998; Sun et al., 1998; Goebel and Poosch, 1999; 
Sun et al., 2000; Al-Hallaq et al., 2002; Eriksson et al., 2002; Naassila and Daoust, 2002; 
Sasaki et al., 2002; Wong et al., 2002; Mueller and Meador-Woodruff, 2003, 2004, 2005; 
Perez-Otano et al., 2006; Eriksson et al., 2007a; Nilsson et al., 2007b; Henson et al., 
2008; Bendova et al., 2009; Roberts et al., 2009).  Despite having a roughly similar 
expression profile across species, future studies with a finer level of analysis may reveal 
important differences.  Further heterogeneity of NR3A expression across species and 
brain regions could also arise from differential expression of its two splice variants 
(discussed above).   
 In contrast to NR3A, NR3B levels are low around postnatal day (P) 10 and 
gradually increase into adulthood within the neocortex, hippocampus, striatum, 
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cerebellum, brainstem, and spinal cord (Andersson et al., 2001; Nishi et al., 2001; 
Eriksson et al., 2002; Matsuda et al., 2002; Bendel et al., 2005; Wee et al., 2008) (Figure 
1.3a).  Given the functional similarities and high sequence homology between NR3A and 
NR3B (57%) (Andersson et al., 2001), it is surprising that these dominant-negative 
subunits have distinct temporal expression patterns in many of the same brain regions. 
 Each NMDAR subunit (NR1, NR2A-D, and NR3A-B) exhibits a unique 
ontogenetic profile in the rodent (Watanabe et al., 1992; Monyer et al., 1994; Sheng et 
al., 1994; Ciabarra et al., 1995; Dunah et al., 1996; Laurie et al., 1997; Sun et al., 1998; 
Matsuda et al., 2002; Fukaya et al., 2005) (Figure 1.3a), consistent with its functional  
“signature” (Goebel and Poosch, 1999; Al-Hallaq et al., 2002).  The NR1 subunit is 
obligatory for NMDAR function and is present throughout life.  NR3A is 
developmentally expressed following a time course most similar to NR2D; both are 
prominent in the first two postnatal weeks in overlapping brain regions (Watanabe et al., 
1992; Monyer et al., 1994; Ciabarra et al., 1995; Dunah et al., 1996; Laurie et al., 1997; 
Sun et al., 1998).  The developmental decreases of NR3A and NR2D expression are in 
contrast to that of NR3B, NR2A, and NR2C, whose expression levels increase 
developmentally and peak during the third postnatal week (Monyer et al., 1994; Sheng et 
al., 1994; Matsuda et al., 2002; Fukaya et al., 2005) (Figure 1.3a).   While both NR3A 
and NR2B are strongly expressed early in development, NR3A (but not NR2B) levels 
exhibit a pronounced reduction during postnatal maturation. 
 
Cellular, laminar, and subcellular localization 
 NR3A and NR3B are expressed by multiple neuronal cell types, including 
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interneurons, pyramidal cells, motor neurons, trigeminal neurons, retinal ganglion and 
amacrine cells (Ishihama et al., 2005; Ishihama and Turman, 2006; Matsuda et al., 2002; 
Mueller and Meador-Woodruff, 2005; Nishi et al., 2001; Paarmann et al., 2005; Sucher et 
al., 2003). Although NR3A is present in oligodendrocytes, it does not seem to be 
expressed in astrocytes (Ishihama et al., 2005; Karadottir et al., 2005; Matsuda et al., 
2002; Paarmann et al., 2005; Perez-Otano et al., 2006; Salter and Fern, 2005).  NR3B 
localization has been observed in most of the cells located in adult cerebral cortex, 
hippocampus, striatum, cerebellum, and lumbar spinal cord.  This ubiquitous expression 
of NR3B parallels that of NR1 and suggests a role for NR3B in adult NMDAR function 
(Wee et al., 2008).  Data from NR3B knockout mice will be required to determine the 
extent to which NR3B influences NMDAR-mediated transmission in the adult central 
nervous system. 
Because of the inside-out pattern in which cortical lamination occurs, the high 
levels of NR3A observed in layer 5 have raised the possibility that NR3A may play a role 
in establishing early cortical circuits, perhaps by modulating Ca
2+
 influx and cell 
vulnerability to excitotoxicity (Mueller and Meador-Woodruff, 2005; Sucher et al., 
1995).  NR3B also shows predominant expression in layer 5, but the implications of this 
laminar specificity in the adult have not yet been investigated.   
Ultrastructurally, NR3A colocalizes with NR1 and NR2 subunits at postsynaptic 
membranes of asymmetric (excitatory) synapses (Perez-Otano et al., 2006; Wong et al., 
2002), although it appears to be more abundant at perisynaptic and extrasynaptic sites 
than at the postsynaptic density (PSD) in both juvenile and adult animals (Perez-Otano et 
al., 2006).  The localization of NR3A contrasts sharply with the PSD-centric localization 
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of NR2A, but is similar to the more lateral and extrasynaptic positioning of NR2B-
containing receptors (Groc et al., 2006; Racca et al., 2000).  Biochemical fractionation 
studies confirm the ultrastructural data, and show that NR3A is associated with 
membranous fractions, such as ER, Golgi, endosomes, and synaptic membranes, but is 
not as enriched in PSDs as NR1 or NR2 subunits (Perez-Otano et al., 2006).  Future 
experiments are needed to determine (1) whether NR3A-containing receptors shift from 
synaptic to extrasynaptic sites during development, as has been suggested for other 
NMDAR subtypes (Kohr, 2006), or (2) whether their peri/extrasynaptic localization 
indicates a graded and reciprocal organization of different NMDAR subtypes within the 
PSD that could be fitted for sensing the varied patterns of glutamate release. 
 
NR3 subunits exert a dominant-negative effect upon NMDAR function 
 
 The properties of typical NMDARs containing NR2A or NR2B subunits include 
channel block by Mg
2+
 at hyperpolarized potentials, high permeability to Ca
2+
, and a 
subunit-specific complement of protein binding partners (Kennedy et al., 2005; Matute et 
al., 1997). These properties are critical to many forms of plasticity (Gustafsson and 
Wigstrom, 1988; Madison et al., 1991) and profoundly influence the wiring of the 
nervous system and memory processes (Constantine-Paton et al., 1990; Bliss and 
Collingridge, 1993).  Receptors containing NR3A or NR3B subunits have unique 
properties that differ from conventional NR1/NR2 heteromers.  In heterologous 
expression systems, NR3 subunits assemble into two functional receptor combinations: 
(1) a heterodimer of NR1 and NR3 subunits that unexpectedly forms an excitatory 
glycine receptor, and (2) a heterotrimeric complex of NR1, NR2, and NR3 subunits that 
forms an NMDAR with novel properties and attenuated currents compared to NR1/NR2 
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NMDARs (Chatterton et al., 2002; Ciabarra et al., 1995; Das et al., 1998; Sucher et al., 
1995).   
 
Triheteromeric NR3A-containing glutamate receptors 
 
NR3A-containing NMDARs only sense glutamate when glutamate-binding NR2 
subunits are included (Ciabarra et al., 1995; Perez-Otano et al., 2001; Sucher et al., 1995) 
(Figure 1.4).  When NR1, NR2A, and NR3 subunits are co-expressed in heterologous 
expression systems, single-channel recordings reveal two populations of NMDA-evoked 
currents:  one characterized by a large conductance resembling the prototypical channel 
response of NR1/NR2A heteromers, and a second population of smaller conductance, 
presumably due to channels containing NR3 (Das et al., 1998; Perez-Otano et al., 2001; 
Sasaki et al., 2002; Ulbrich and Isacoff, 2008) (Figure 1.4B, C).  The putative NR3-
containing receptors exhibit dramatically reduced single-channel open probabilities and 
longer mean open times (Perez-Otano et al., 2001; Sasaki et al., 2002, but see (Das et al., 
1998). 
Along with generally decreasing ionic conductance through NMDARs, inclusion 
of NR3 subunits alters two of the most prominent properties of traditional NMDARs 
(NR1/NR2 heteromers).  First, it causes a five- to ten-fold decrease in Ca
2+
 permeability, 
with the variation of the estimates likely reflecting differences between the recombinant 
systems employed (Das et al., 1998; Matsuda et al., 2002; Perez-Otano et al., 2001; 
Sasaki et al., 2002; Tong et al., 2008) (Figure 1.4A).  Second, NR3A-containing 
NMDARs are also almost completely insensitive to Mg
2+
 block at hyperpolarized 
potentials (Sasaki et al., 2002, but see Nishi et al., 2001).  Both the reduced Mg
2+ 
sensitivity and Ca
2+
 permeability of NR3A-NMDARs have recently been confirmed in 
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neuronal cultures or hippocampal slices from transgenic mice overexpressing NR3A and 
knockout mice lacking NR3A (Roberts et al., 2009; Tong et al., 2008) (Table 1.2).  As 
previously discussed in Section 2, the observed physiological characteristics of NR3A-
containing NMDARs most likely result from the formation of a narrow constriction of 
the outer vestibule along the TM3 pore-forming region of the NR3 subunits. 
 
Diheteromeric NR3A-containing excitatory glycine receptors 
 
The physiological significance of NR1/NR3 excitatory glycine receptors remains 
an open question because of conflicting reports in vitro, and this subunit combination has 
yet to be documented in vivo.  Despite evidence that NR1/NR3 complexes are targeted to 
the plasma membrane in heterologous systems (Madry et al., 2007; Perez-Otano et al., 
2001), early reports failed to record NMDAR-mediated responses to glutamate or NMDA 
application in the absence of NR2 subunits (Ciabarra et al., 1995; Das et al., 1998; Perez-
Otano et al., 2001; Sucher et al., 1995).  Instead of exhibiting responsiveness to 
glutamate, NR1/NR3 complexes were found to be sensitive to glycine application 
(Chatterton et al., 2002).  This finding is consistent with the observation that the NR3A 
ligand binding domain has very high affinity for glycine, but is relatively insensitive to 
glutamate (Nilsson et al., 2007a; Yao and Mayer, 2006).  Glycine application to 
NR1/NR3 diheteromers evokes a large inward current, indicating that these receptors 
form an excitatory glycine receptor.  The ion permeability of NR1/NR3 diheteromers was 
similar to that of NR3-containing triheteromers, in that the currents were relatively 
impermeable to Ca
2+
 and insensitive to Mg
2+
 block (Chatterton et al., 2002; Das et al., 
1998; Nishi et al., 2001; Perez-Otano et al., 2001; Sasaki et al., 2002).  Additionally, 
while both NR1/NR3A and NR1/NR3B receptors form in Xenopus oocytes (Chatterton et 
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al., 2002), NR3 subunits fail to assemble with NR1 subunits in HEK cells unless both 
NR3A and NR3B are present (Smothers and Woodward, 2007). 
Chatterton and colleagues (2002) reported that bath application of glycine to 
cerebrocortical cultures elicited a bursting response, which they interpreted as evidence 
that excitatory glycine receptors exist in the brain.  Furthermore, single-channel 
recordings from outside-out patches from these cultured neurons exhibited channel 
properties similar to NR1/NR3 receptors in heterologous systems.  However, this 
bursting response to glycine can be found in cultures in which NR1 subunits, and hence 
all NMDARs, are lacking (Matsuda et al., 2003).  Given that the presence of NR1 is 
required for NR3 subunits to exit the ER and form stable complexes in the plasma 
membrane (Perez-Otano et al., 2001), these data indicate that the glycine-induced 
bursting may be independent of NR3 subunits.  The existence of glycinergic NR1/NR3 
receptors was also questioned by studies finding no evidence for excitatory glycine 
currents in cultured neurons from mice genetically engineered to overexpress NR3A 
(Tong et al., 2008) (Table 1.2). 
The high affinity of NR1/NR3 receptors for glycine suggests that, if found in vivo, 
this receptor combination might be saturated by physiological concentrations of glycine 
(Yao and Mayer, 2006).  Thus, these receptors would serve to keep neurons in a more 
depolarized state and, depending upon their subcellular localization, could have a 
profound influence upon synaptic transmission and action potential firing.   
 
NR3A pharmacology 
 
Agonists 
 
The study of NR3A pharmacology is still in its infancy.  However, it is clear that 
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NR3A shares more commonalities with NR1 than it does with NR2 subunits.  For 
instance, NR1 binds glycine (Hirai et al., 1996; Yao and Mayer, 2006) whereas NR2 
subunits bind glutamate (Laurie et al., 1997), and receptors formed by NR1 and NR3A 
bind glycine with much higher affinity than do NR1/NR2 receptors (Chatterton et al., 
2002).  Studies of the rodent ligand binding domain and human full-length protein 
confirm that glycine binds NR3A with much higher affinity than it binds NR1 [rodent 
NR3A, Kd = 40 nM, 650 times less than that for NR1 (Yao and Mayer, 2006), and human 
NR3A, Kd = 535 nM (Nilsson et al., 2007a)]. The lower affinity for glycine of human 
NR3A compared to rodent NR3A could be due to species differences or differences 
between the full-length protein and the truncated soluble ligand binding domain.  In both 
human and rodent, NR3A is likely saturated by its preferred endogenous ligand, glycine, 
at physiological concentrations (Yao and Mayer, 2006).  The NR3A ligand binding 
domain has a low affinity for glutamate (Kd = 9.6 mM) (Yao and Mayer, 2006), and the 
presumptive activation of NR1/NR2/NR3A triheteromeric receptors by glutamate or 
NMDA is almost certainly due to the binding of these agonists to NR2 subunits.   
D-serine is a potent glycine site agonist of NMDARs (Kleckner and Dingledine, 
1988), and accordingly, binding assays demonstrate that D-serine also binds human and 
rat NR3A with high affinity (Nilsson et al., 2007a; Yao and Mayer, 2006).  One 
electrophysiological study indicated that D-serine behaves as a functional antagonist of 
NR1/NR3A receptors (Chatterton et al., 2002).  This differs from other reports, and may 
be due to the fact that D-serine produces a rapid desensitization resembling an antagonist 
block (Yao and Mayer, 2006).  Another possibility is that assembly of NR3A with other 
subunits (e.g. NR1) produces allosteric interactions that alter ligand binding properties 
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(Laurie and Seeburg, 1994).  The ligand binding properties of NR3A, and if/how they 
differ when NR3A co-assembles with other NMDAR subunits have yet to be determined.  
Until these limitations are overcome, caution should be used when interpreting whether 
NR3A-containing NMDARs are present or absent based on the effects of 
pharmacological agonists/antagonists such as D-serine (Li and Han, 2006). 
While NR3A shares more attributes with NR1 than with NR2 subunits, there are 
nonetheless striking pharmacological differences between NR1 and NR3A subunits 
(Awobuluyi et al., 2007; Nilsson et al., 2007a; Yao and Mayer, 2006).  For example, 
NR1 binds the partial agonist ACPC (1-aminocyclopropanecarboxylic acid) with higher 
affinity than ACBC (1-aminocyclobutane-1-carboxylic acid), while the converse is true 
for NR3A (Yao and Mayer, 2006).  Moreover, neither the partial agonist D-cycloserine 
nor the antagonist 7-chlorokynurenic acid displace glycine binding to human NR3A 
expressed in HEK cells (Nilsson et al., 2007a), in contrast to what is observed for the 
binding of glycine to NR1.  The differences between NR1 and NR3A subunits raise the 
exciting possibility that NR3A-specific agonists or antagonists could be generated in the 
future to target diseases of NMDAR dysfunction.   
 
Antagonists 
 
 Very little is known about how NR3A-containing receptors can be 
pharmacologically blocked.  Studies to date have focused on the binding of NR1 
antagonists to NR3A or have used electrophysiological measures to determine how 
NR1/NR3A or NR1/NR2/NR3A heteromers respond to typical NMDAR antagonists.  
When NR1/NR3A diheteromers are expressed in heterologous systems, they exhibit little 
electrophysiological block by the classic NMDAR antagonists APV (competitive), MK-
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801 (non-competitive), or memantine (uncompetitive) (Chatterton et al., 2002).  
Triheteromeric receptors containing NR1/NR2/NR3A are more difficult to isolate 
electrophysiologically because they must be distinguished from either NR1/NR2 or 
NR1/NR3A receptors.  However, this has been possible using single-channel recordings, 
which showed that the small conductance NR1/NR2A/NR3A channel is blocked by D-
APV (200 M) (Sasaki et al., 2002).  Interestingly, NR1/NR2/NR3A triheteromeric 
receptors may also be blocked by antagonists targeting NR2 subunits, as receptors 
composed of NR1/NR2B/NR3A triheteromers and NR1/NR2B diheteromers are similarly 
blocked by high concentrations of the NR2B-antagonist ifenprodil (Smothers and 
Woodward, 2003).  One might predict that, compared to NR1/NR2B diheteromers, 
NR1/NR2B/NR3A triheteromers might be less sensitive to lower concentrations of 
ifenprodil where NR2B-specificity is greater, as previous studies have shown that the 
magnitude of ifenprodil block depends on the number of NR2B subunits contained within 
the NMDAR complex (Hatton and Paoletti, 2005).  
 Studies of the ligand binding domain demonstrate that NR3A subunits interact 
with classical NMDAR antagonists.  Six of eight NR1 subunit antagonists exhibit more 
than a 100-fold larger affinity for NR1 subunits compared to NR3A subunits (Yao and 
Mayer, 2006).  For example, kynurenic acid binds the NR1 ligand binding domain with 
high affinity (Kd= ~53 M) but only weakly binds the NR3A binding domain (Kd = ~15 
mM) (Yao and Mayer, 2006).  These observations provide further evidence that NR1 and 
NR3A have distinct ligand binding properties and increase the likelihood that specific 
agonists/antagonists could be designed to target NR3A selectively.  However, the 
extremely high affinity of NR3A for glycine indicates that the design of competitive 
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antagonists would require a particularly high affinity compound.  Thus, it might be more 
feasible to design non-competitive antagonists that act via allosteric interactions with 
NR3A-containing NMDARs.  
 
Intracellular binding partners 
 
 NMDAR-mediated effects can be initiated directly via ionic flow through the 
channel pore, and can also be shaped by intracellular partners tethered to the NMDAR 
complex.  To date, few studies have examined interactions of NR3A with other proteins, 
but the existing reports have identified possible associations between NR3A and protein 
phosphatases, cytoskeletal proteins, and an adaptor protein implicated in receptor 
trafficking. 
 One specific C-terminal binding partner of NR3A is the catalytic subunit of 
protein phosphatase 2A (PP2A) (Chan and Sucher, 2001; Ma and Sucher, 2004) (Figure 
1.2).  PP2A plays important roles at postsynaptic sites, including dephosphorylating NR1 
subunits on serine 897 (NR1-S897).  Dephosphorylation of NR1-S897 by PP2A 
attenuates NMDAR single-channel currents and reduces permeability of the receptors to 
Ca
2+
.  Importantly, activation of NMDARs causes the physical uncoupling between 
NR3A and PP2A, decreasing PP2A activity at the synapse.  By influencing NR1 
phosphorylation through its interaction with PP2A, NR3A may provide a feedback 
mechanism to modulate NMDAR function based on the history of synaptic activity (Chan 
and Sucher, 2001).  Intriguingly, brains from schizophrenic patients have increased 
dephosphorylation of NR1-S897 (Emamian et al., 2004) that might be related to 
overexpression of NR3A (Ma and Sucher, 2004), providing a potential mechanism that 
could contribute to the NMDAR hypofunction observed in schizophrenia. 
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 In addition to modulating the activity of a phosphatase important to NMDARs, 
one intracellular NR3A binding partner appears to be crucial for the removal of nascent 
NMDARs during synapse maturation.  NR3A binds PACSIN1/syndapin1, a neuron-
specific intracellular adaptor (Perez-Otano et al., 2006).  PACSIN1 binds selectively to 
the C-terminus of NR3A (Figure 1.2) through tertiary structure interactions with its NPF 
(Asn/Pro/Phe) motifs, recruiting a larger complex with the endocytic proteins dynamin 
and clathrin and facilitating the rapid endocytosis of NR3A-containing NMDARs.  
Disruption of this interaction results in the synaptic accumulation of NR3A-containing 
NMDARs.  The PACSIN1-mediated removal of NR3A-containing NMDARs is activity-
dependent, providing a mechanism for regulated receptor replacement that could drive 
the functional maturation of synaptic NMDARs during postnatal development and the 
associated changes in the properties of synaptic plasticity. 
 Additional putative NR3A binding partners are beginning to be identified which 
could alter its localization, trafficking, and signaling (Figure 1.2), but these interactions 
were only shown in vitro and need to be extensively studied and verified.  NR3A may 
interact with a cytoskeletal protein (MAP1S/C19ORF5), a scaffolding protein (plectin), a 
cell cycle and apoptosis regulatory protein (CARP-1), and a regulator of G-protein 
signaling (GPS2/AMF1) (Eriksson et al., 2007a; Eriksson et al., 2007b).  Confirmation of 
these associations would position NR3A to play roles in intracellular processes such as 
trafficking and targeting of NR3A-containing receptors (MAP1S and plectin), PKC 
activation (plectin), and suppression of the MAPK pathway (GPS2/AMF1).  Other NR3A 
binding partners will undoubtedly be identified, which may link NR3A to more signaling 
pathways.  Notably, there is a conspicuous absence of NR3A interaction with the 
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postsynaptic scaffolding protein PSD-95 (Eriksson et al., 2007a; Matsuda et al., 2002), 
which may explain the labile synaptic expression of NR3A-containing NMDARs (Perez-
Otano et al., 2006).  Alternatively, the clustering and stabilization of NR3A-containing 
receptors near synaptic sites may rely on NR2 anchoring with other membrane-associated 
guanylate kinase family scaffolding proteins, such as SAP102, which are present at high 
levels in developing synapses (Perez-Otano et al., 2006; Sans et al., 2000; Wong et al., 
2002). 
 
Assembly, trafficking, and targeting of NR3-containing NMDARs 
 
Developmental regulation of the membrane expression of different NMDAR 
subtypes shapes synaptic and behavioral plasticity (Isaac et al., 1995; Liao et al., 1995; 
Philpot et al., 2001; Quinlan et al., 1999; Roberts et al., 2009; Rumpel et al., 1998; 
Sawtell et al., 2003; Tang et al., 1999; Wu et al., 1996).  NMDARs can rapidly 
translocate in and out of synaptic regions by lateral diffusion in the plane of the 
membrane and by endo/exocytic trafficking.  It is increasingly recognized that regulation 
of trafficking contributes to the synapse-specific and activity-dependent control of 
NMDAR expression at individual synapses, by favoring local receptor removal, insertion, 
or exchange (Lavezzari et al., 2004; Montgomery et al., 2005; Scott et al., 2004; 
Washbourne et al., 2004). 
Although peak expression of rodent NR3A occurs in the second postnatal week, 
its expression levels and association with NR1 subunits may nonetheless be fairly limited 
compared to that of NR2 subunits.  Immunoprecipitation experiments found that, despite 
the majority of NR3A associating with the obligatory NR1 subunit, NR3A subunits are 
likely to contribute only a small fraction of the total receptor complex composition (Al-
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Hallaq et al., 2002).  Specifically at age P10, approximately 80% of NR3A subunits are 
associated with NR1, but less than 10% of NR1, NR2A, and NR2B are bound to NR3A, 
and this association decreases further over development.  Strikingly, NR3A genetic 
deletion studies demonstrate that even a low NR3A abundance is sufficient to have 
profound consequences on synapse formation and NMDAR-mediated transmission 
during early postnatal development (Das et al., 1998; Perez-Otano et al., 2001; Roberts et 
al., 2009; Sasaki et al., 2002; Tong et al., 2008). 
Protein degradation, fluorescence recovery after photobleaching, and fluorescence 
resonance energy transfer experiments suggest a central role for NR1 in the folding and 
assembly of NMDAR heteromers in the endoplasmic reticulum (ER) (Atlason et al., 
2007; Schuler et al., 2008).  Homomeric NR3 complexes fail to exit the ER, presumably 
because the C-terminus of NR3A/NR3B carries a putative ER retention signal (RXR) 
(Figure 1.2).  For forward secretory trafficking and functional insertion into the plasma 
membrane to occur, the RXR motif is likely masked by heteromeric assembly with NR1 
subunits (Matsuda et al., 2003; Perez-Otano et al., 2001; Schuler et al., 2008; Scott et al., 
2001; Standley et al., 2000).  However, NR3 subunits may be rapidly degraded, even in 
the presence of NR1, resulting in inefficient assembly mechanisms or extremely rapid 
turnover of NR3A-containing NMDARs lacking NR2 subunits (Atlason et al., 2007). 
Once at the plasma membrane surface, the abundance and synaptic targeting of 
NR3A-containing NMDARs appears to be highly regulated by synaptic activation of 
NMDARs.  In experiments using cultured hippocampal neurons transfected with GFP-
tagged NR3A, intrinsic neuronal activity induces the movement of NR3A-containing 
NMDARs from membrane and synaptic locations to intracellular compartments (Perez-
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Otano et al., 2006). 
Endocytic removal of NR3A can be facilitated by bath application of NMDA and 
prevented by disruption of synaptic activity (TTX) or antagonism of NMDARs with 
APV.  Furthermore, removal relies upon a selective interaction with 
PACSIN1/syndapin1, a specialized accessory protein involved in clathrin-mediated 
endocytosis and enriched at synapses (discussed in more detail in Section 6).  The 
synaptic expression of PACSIN1 is developmentally regulated and exhibits a reciprocal 
expression pattern to that of NR3A (Perez-Otano et al., 2006), supporting a role for 
PACSIN1 in the developmental downregulation of NR3A subunits.  
 Another regulator of NR3A synaptic targeting is the protein phosphatase PP2A, 
which binds NR3A directly and influences the dephosphorylation state of NR1 subunits 
(Chan and Sucher, 2001; Ma and Sucher, 2004).  PACSIN1 and PP2A binding domains 
on the C-terminus of NR3A overlap (Figure 1.2), making it unlikely that these proteins 
would bind concurrently (Chan and Sucher, 2001; Perez-Otano et al., 2006).   
Interestingly, NMDAR activation disrupts the PP2A-NR3A protein interaction, and may 
unmask binding sites for PACSIN1, enabling NR3A endocytosis.    
Finally, PDZ-domain binding motifs, which provide areas of attachment for 
prototypical PSD proteins and support the postsynaptic anchoring of other NMDAR 
subunits, are absent in the C-termini of NR3A and NR3B (Eriksson et al., 2007a; 
Matsuda et al., 2002).  Perhaps as a consequence, these subunits are more loosely 
attached to the PSD than NR2 subunits (Perez-Otano et al., 2006; Roberts et al., 2009).  
Despite this emerging set of data, and in contrast to the large literature on NR2 subunits, 
little is yet known about how and where NR3 proteins traffic. 
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Rationale for Dissertation Research 
 
Developmental and experience-dependent changes in NMDAR subtypes dictate 
the function of the receptor.  Although the NR3 subfamily was discovered over fifteen 
years ago, most research has ignored the NR3A and NR3B subunits and has instead 
focused on the canonical subtypes predominant in the forebrain, NR2A and NR2B.  
However, recent studies have suggested that the NR3A subunit is also present and may 
have an important role in excitatory synapse development during early postnatal life. 
 Genetic manipulations of NR3A levels suggest this subunit influences 
synaptogenesis.  NR3A knockouts exhibit a striking increase in the number of dendritic 
spines (Das et al., 1998), while NR3A-overexpressors have reduced synapse density 
(Roberts et al., 2009), suggesting that NR3A may play a key role in spine and synapse 
formation and elimination.  Electron microscopy analysis shows not only reduced 
synapse numbers and postsynaptic density (PSD) length in the NR3A overexpressors, but 
also a sharp decrease in the number of NR3A particles with increasing synapse size 
(Roberts et al., 2009).  This occurred while NR1 particles were roughly constant, 
suggesting that NR3A is normally absent from large synapses and is targeted to small 
synapses. Altogether, these data indicate a dominant role of NR3A in limiting 
synapse/spine growth. 
The synaptic removal of NR3A-containing NMDARs is thought to be a trigger for 
synapses to gain a more mature complement of NMDAR subtypes and to enable robust 
forms of synaptic plasticity (Perez-Otano et al., 2006).  NR3A has been shown to 
associate with NR1, NR2A, and NR2B at extra- and perisynaptic sites (Perez-Otano et 
al., 2006), although neither the subcellular localization nor the prevalence of NR3A-
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containing receptors has been rigorously established.  NR3A is in the right place at the 
right time to influence spine and synapse development, but it is unclear whether its 
influence is to serve as a ‘synaptic brake’ to limit synapse/spine formation or if it acts as 
a ‘synaptic marker’ to promote synapse elimination.  I hypothesized that NR3A 
suppresses NMDAR activity during early life, a period of tremendous neuronal 
outgrowth, to prevent premature synaptic strengthening and stabilization.  
Proper synapse formation and refinement in the CNS during childhood enable us 
to perceive and respond to our external environment.  Not surprisingly, improper 
formation or function of these synapses leads to many neurodevelopmental disorders, 
including autism and schizophrenia (Zoghbi, 2003). The unique properties of NR3A 
suggest that this subunit is well-positioned to dramatically influence synapse maturation, 
and the improper expression of this subunit is likely to have profound effects on synaptic 
connectivity.  Whether NR3A plays a role in the pathophysiology of the synaptic 
disorder, schizophrenia is a key question addressed by this dissertation.   
Schizophrenia arises from aberrant development, stabilization, and plasticity of 
synapses in the human prefrontal cortex (Javitt and Zukin, 1991; Olney et al., 1999; 
Coyle et al., 2003). Recent data raise the intriguing possibility that NMDAR 
hypofunction in schizophrenia might arise from an aberrant increase in NR3A expression, 
as NR3A suppresses NMDAR function and NR3A mRNA transcript levels are 
significantly elevated in the dorsolateral prefrontal cortex (DLPFC) of schizophrenic 
patients (Mueller and Meador-Woodruff, 2004).  In this same region where NR3A is 
overexpressed, spine densities are reduced in schizophrenic patients (Glantz and Lewis, 
2000, 2001). Because NR3A likely has a strong influence on limiting spine density, I 
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hypothesized that a lack of the normal developmental downregulation of NR3A could 
result in significant reductions in spine numbers.  NR3A’s unique ability to suppress 
NMDAR function makes it an extremely attractive candidate, both as an endogenous 
contributor to the NMDAR hypofunction observed in schizophrenia and as a potential 
target for pharmacological interventions.  
Little is known about the physiological importance of having NR3A-containing 
NMDARs during early development.  My experiments are among the first to define the 
role of NR3A in synapse development and these data along with others are forcing a re-
evaluation of the classical view of NMDAR-dependent synapse maturation.  Examining 
the role of NR3A in synaptic stabilization during early postnatal development will be 
crucial to understanding a key process in the refinement of neural circuits capable of 
learning and storing memories. 
 26
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27
 
 
Figure 1.2  Legend appears on the following page. 
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CHAPTER 2 
 
 
NR3A and NR1 in Human Development 
 
Abstract 
 
Subunit composition of NMDA-type glutamate receptors (NMDARs) dictates 
their function, yet the ontogenic profiles of human NMDAR subunits from gestation to 
adulthood have not been determined.  We examined NMDAR mRNA and protein 
development in human dorsolateral prefrontal cortex (DLPFC), an area in which 
NMDARs are critical for higher cognitive processing and NMDAR hypofunction is 
hypothesized in schizophrenia.  Using quantitative RT-PCR and western blotting, we 
found NR1 expression begins low prenatally, peaks in adolescence, yet remains high 
throughout life, suggesting lifelong importance of NMDAR function.  In contrast, NR3A 
levels are low during gestation, surge soon after birth, and decline progressively through 
adolescence and into adulthood.  Because NR3A subunits uniquely attenuate NMDAR-
mediated currents, limit calcium influx, and suppress dendritic spine formation, high 
levels during early childhood may be important for regulating neuroprotection and 
activity-dependent sculpting of synapses.  We also examined whether subunit changes 
underlie reduced NMDAR activity in schizophrenia.  Our results reveal normal NR1 and 
NR3A protein levels in DLPFC from schizophrenic patients, indicating that NMDAR 
hypofunction is unlikely to be maintained by gross changes in NR3A-containing 
NMDARs or overall NMDAR numbers. These data provide insights into NMDAR 
 34
functions in the developing CNS and will contribute to designing pharmacotherapies for 
neurological disorders. 
 
Introduction 
 
NMDA-type ionotropic glutamate receptors (NMDARs) are involved in a wide 
array of biological processes crucial for brain development and function.  In addition to 
modulating neuronal and synapse maturation in development (Perez-Otano and Ehlers, 
2004), NMDARs are responsible for short-term and long-term memory storage through 
mechanisms of synaptic plasticity (Malenka and Nicoll, 1999).  For example, many 
executive functions and working memory tasks require NMDAR activity in the prefrontal 
cortex (Lisman et al., 1998; Durstewitz and Gabriel, 2007), suggesting that disruption of 
these receptors could cause profound cognitive deficits (Goldman-Rakic, 1995; Lewis, 
1997).  Given the diverse roles of NMDARs, it is not surprising that NMDAR 
dysfunction is thought to underlie several neurological and psychiatric disorders.  
Accordingly, a major goal in neuroscience is to understand how NMDARs normally 
change during human development and how this might be altered in disease states.  
NMDAR function is dictated by its subunit composition (Monyer et al., 1992).  
NMDARs are tetramers consisting of essential NR1 subunits in combination with NR2 
(A-D) or NR3 (A-B) subunits that provide functional molecular diversity (Perez-Otano et 
al., 2001; Al-Hallaq et al., 2002; Matsuda et al., 2003).  However, unlike the conventional 
NR1/NR2 receptors, those containing the recently identified NR3 subunits exhibit 
decreased single-channel conductance, insensitivity to magnesium blockade, and reduced 
calcium (Ca
2+
) permeability (Das et al., 1998; Perez-Otano et al., 2001; Chatterton et al., 
2002; Sasaki et al., 2002).  Because Ca
2+
 influx is responsible for many forms of synaptic 
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plasticity (Malenka and Bear, 2004) and excitotoxic cell death (Choi, 1988), the inclusion 
of NR3 subunits into NMDARs is likely to critically regulate the properties of NMDAR-
mediated plasticity and may also serve a neuroprotective role. 
Developmental regulation of human NMDAR subunits is poorly understood.  
Such knowledge is important for the rational design of pharmacotherapies for diseases 
involving NMDAR subunit dysfunction, such as neurodegenerative conditions, stroke, 
epilepsy, neuropathic pain, and schizophrenia (reviewed in (Cull-Candy et al., 2001; 
Waxman and Lynch, 2005; Kristiansen et al., 2007).  For example, existing treatments for 
schizophrenia are very limited in their specificity and efficacy (Ross et al., 2006).  This 
disease is thought to arise from decreased NMDAR activity that disrupts normal synaptic 
connectivity and plasticity, especially within the dorsolateral prefrontal cortex (DLPFC) 
(Javitt and Zukin, 1991; Olney et al., 1999; Lewis and Levitt, 2002; Coyle et al., 2003; 
Frankle et al., 2003).  While there is little consistent evidence that overall NR1 and NR2 
levels differ between schizophrenic patients and controls (Kristiansen et al., 2007), a 
recent study suggests that NR3A may be elevated within the schizophrenic DLPFC 
(Mueller and Meador-Woodruff, 2004).  Therefore, NR3A’s unique ability to suppress 
NMDAR function makes it an extremely attractive candidate both as an endogenous 
contributor to the NMDAR hypofunction observed in schizophrenia and as a potential 
target for pharmacological interventions. 
To reveal how NMDAR subunit composition changes through the course of brain 
development, and to begin to understand whether NMDAR subunits are altered in 
schizophrenia, we used postmortem tissue to examine NMDAR subunits, NR3A and 
NR1, during normal human DLPFC development and in the DLPFC of schizophrenic 
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patients.  Additionally, we demonstrate the effects of antipsychotic medications on 
NMDAR subunits.  To our knowledge, we provide the first systematic evaluation of the 
normal developmental profiles of NMDAR expression in maturation of the human 
prefrontal cortex from mid-gestation to early adulthood. 
 
Materials and Methods 
 
Postmortem Human Samples 
 
Postmortem human tissue samples were de-identified to protect personal health 
information.  Samples from the developmental cohort contained uniform 1 cm coronal 
sections of prefrontal cortex (Brodmann areas 9/46) from 45 subjects ranging in age from 
18 weeks gestation through 25 years (Table 1).  Frozen tissue was obtained from the 
NICHD-University of Maryland Brain and Tissue Bank for Developmental Disorders 
under contracts N01-HD-4-3368 and N01-HD-4-3383.  Individuals died from non-CNS 
causes and had no known history of substance abuse or major psychiatric disorders.  A 
priori, samples were divided into 7 age groups established in a previous study (Glantz et 
al., 2007):  prenatal (n=6), birth to 12 months of age (n=5), one to five years (n=6), six to 
ten years (n=6), eleven to fifteen years (n=11), sixteen to twenty years (n=4), and twenty-
one to twenty-five years (n=7).  The schizophrenia cohort consisted of Brodmann area 9 
tissue samples from 35 subjects (control n=20; schizophrenia n=15) obtained from the 
Harvard Brain Tissue Resource Center (McLean, MA; supported in part by PHS grant 
number R24 MH068855), with ages ranging from 21 to 80
+
 years (Table 2).  To protect 
personal health information, exact ages were used for statistical purposes, but only age 
ranges of subjects can be published.  Prefrontal cortex samples in the schizophrenia and 
control groups were group-matched for age, gender, ethnicity, side-of-brain, brain pH, 
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and postmortem interval (PMI).  All fresh frozen tissue blocks from the UMD and 
Harvard collections were chipped from larger frozen cortical slabs and consisted 
primarily of gray matter with small amounts of underlying white matter.  The samples 
from the UMD tissue collection were harvested as 1 cm coronal slabs.  Cuts were made 
with guidance from a neuroanatomical atlas to select Brodmann areas 9 and 46, and 
immediately frozen at -80°C.  Cytoarchitectonic localizations of Brodmann areas 9 and 
46 were ascertained using Nissl staining of sections cut immediately adjacent to tissue 
blocks used for this study (see (Glantz et al., 2007) for details).  Samples of Brodmann 
area 9 from the Harvard tissue were obtained through uniform dissection from the 
superior prefrontal gyrus according to the Brodmann map.  All tissue was stored frozen at 
-80°C until use.  Tissue pH was measured as described (Salimi et al., 2008) and samples 
with pH < 5.8 were excluded from analysis.  This study was approved by the Biomedical 
Institutional Review Board of the University of North Carolina at Chapel Hill. 
Animal Use 
 
The animal use in this study was approved by the Institutional Animal Care and 
Use Committee of the University of North Carolina at Chapel Hill.  All rodents were 
maintained and sacrificed according to protocol guidelines. 
Postmortem Stability of NMDAR Proteins 
 
Eighteen C57BL/6 mice at age postnatal day 10 (P10) were divided into three 
equal groups, anesthetized with a lethal dose of sodium pentobarbital, and decapitated 
upon disappearance of corneal reflexes.  In the first group, frontal cortex was dissected 
and immediately frozen at -80°C (PMI = 0 hrs).  To approximate the human postmortem 
interval and simulate morgue conditions, heads of the second and third groups were kept 
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at room temperature for 6 hrs, then at 4°C for 6 hrs and 18 hrs, respectively, after which 
time frontal cortices were dissected (PMI = 12 hrs and PMI = 24 hrs) and frozen at -80°C 
until use in immunoblotting analysis (Jarskog et al., 2004). 
Antipsychotic Treatment  
 
Sub-chronic drug treatments were administered to thirty-six singly housed, male 
Sprague–Dawley rats (150–200g, Charles River) as described previously (Jarskog et al., 
2007).  Briefly, animals received daily intraperitoneal injections of haloperidol 
(1mg/kg/day, n=12), clozapine (10 mg/kg/day, n=12), or saline (0.9%, n=12) for 4 weeks.  
One hour after the final dose, rats were killed and anterior right medial frontal cortices 
were dissected.  All tissue was kept frozen at -80°C until use in immunoblotting analysis. 
RNA Extraction, cDNA Preparation, and Quantitative RT-PCR 
 
Total RNA was extracted from pulverized human developmental PFC tissue 
samples using the RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions.  RNA concentrations and quality (mean RNA Integrity 
Number = 8.75 ± 1.0) were determined using Series II RNA 6000 Nano Assay in the 
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).  RNA was reverse transcribed 
using the High Capacity cDNA RT Kit (Applied Biosystems, Foster City, CA) according 
to the manufacturer’s protocol.  Relative expression levels of NMDAR mRNAs were 
measured by quantitative RT-PCR using pre-validated assays for NR1, NR3A, and 
GUSB (-glucuronidase, which served as the endogenous control) (Applied Biosystems 
Assays-on-Demand:  Hs00609557_m1 for NR1, Hs00370290_m1 for NR3A, and 
4333767F for GUSB).  All probes had FAM reporter dye and MGB quencher.  The NR1 
primer-probe combination spanned exon boundary 1-2, covering all eight splice variants, 
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and the NR3A assay covered exon boundary 3-4.   Pilot experiments using cDNA 
dilutions were used to define the dynamic range of each assay.  GUSB was selected from 
several candidate reference genes as the endogenous control most closely matching in 
expression level to the target NMDAR genes.  Reactions were run in a 384-well plate 
format on an ABI 7900HT Fast RT-PCR sequence detection system (Applied 
Biosystems).  Each 20 μl reaction contained 9 μl diluted cDNA (NR1: 6.25ng; NR3A: 
12.5 ng; GUSB: 6.25ng or 12.5ng), 0.9 μM each primer, 0.25 μM probe, and 10 μl 
TaqMan Universal PCR 2X MasterMix with AmpErase UNG (Applied Biosystems) with 
MGB/TAMRA 5’ endonuclease and ROX passive reference dye.  PCR cycle parameters 
were 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 sec, 60°C for 60 sec.    
Each examined mRNA was quantified from a single plate and CT values were within the 
linear range of the standard curve.  All samples were loaded in triplicates.  Reverse 
transcriptase was omitted from control reactions for each tissue sample to verify the 
absence of amplified genomic DNA.  The same threshold and baseline were used for all 
samples.  Three of the 45 human brain samples did not meet our inclusion criteria for the 
mRNA quantification and were thus omitted from analysis. 
Cortical Brain Extracts 
 
Homogenates were prepared from postmortem human, monkey, mouse, and rat 
frontal cortices.  Tissues were homogenized  (1:10, w/v) on ice for 30 sec (PowerGen 
125, Fisher Scientific, Pittsburgh, PA) and sonicated for 10 sec at 10 mV (Sonic 
Dismembrator 60, Fisher Scientific) in ice-cold 50 mM Tris-HCl buffer (pH 7.4) with 0.6 
M NaCl, 0.2% Triton X-100, 1 mM benzamidine, 0.1 mM benzethonium chloride, and 
0.1 mM PMSF (Sigma, St Louis, MO).  Samples were cleared of debris by centrifugation 
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at 4°C for 15 min at 15,000 x g and supernatants were assayed for total protein in 
triplicate using the bicinchoninic acid method (Micro BCA Protein Assay Kit, Pierce 
Chemical, Rockford, IL).  Aliquots were stored at -80°C until use. 
Immunoblotting 
 
Equal amounts of total protein (25-50 μg) were heated for 10 min at 70°C in 
sample buffer and applied to 10-lane 4-12% gradient NuPAGE Novex tris-glycine mini-
gels (Invitrogen, Carlsbad, CA), along with molecular weight markers, a pooled sample 
homogenate, and a mouse frontal cortex sample as positive control.  Coded samples were 
loaded randomly onto gels to preserve the integrity of blinded, unbiased data analyses.  
Samples were resolved by SDS-PAGE at 125V for two hrs.  Separated proteins were then 
electrophoretically transferred (Bio-Rad, Hercules, CA) to nitrocellulose membranes 
(Millipore, Billerica, MA) at 25V overnight at 4°C.   After eliminating nonspecific 
protein binding to membranes with blocking buffer (Odyssey, LI-COR, Lincoln, NE) for 
1 hr at room temperature, membranes were cut into three strips with the aid of molecular 
size markers.  Because the Odyssey Imaging System uses two near-infrared channels to 
detect fluorescent signals, two proteins can be simultaneously probed on each blot strip.  
Thus, six proteins were able to be detected from the same gel (upper blot strip, 
NR2B/NR2A; middle, NR3A/NR1; lower, -tubulin/GAPDH).  This approach allowed 
us to analyze multiple proteins while avoiding complications arising from stripping and 
re-probing membranes.  The following primary antibodies were incubated overnight at 
4°C in 1:1 blocking buffer:phosphate-buffered saline (PBS), at optimized concentrations:  
rabbit anti-pan NR1 (#SC9058, 1:6000, Santa Cruz Biotechnology, Santa Cruz, CA), 
mouse anti-NR1 (#556308, 1:5000, BD/Pharmingen, San Jose, CA), rabbit anti-NR2A 
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(#SC9056, 1:500, Santa Cruz), goat anti-NR2B (#SC1469, 1:10,000, Santa Cruz), mouse 
anti-NR3A (#MAB5388, 1:1000, Chemicon, Temecula, CA), rabbit anti-NR3A (#07-
356, 1:500, Millipore/Upstate), goat anti-GAPDH (#IMG3073, 1:40,000, Imgenex, San 
Diego, CA), and mouse anti--tubulin (#MAB3408, 1:100,000, Millipore/Chemicon).  
Membranes were washed extensively in PBS-0.1% Tween 20  and then incubated at 
room temperature for 1 hr (shielded from light) with appropriate secondary antibodies 
diluted in 1:1 blocking buffer/PBS-0.1% Tween 20:  Alexa Fluor 680-labeled anti-goat 
IgG or anti-mouse IgG (1:5000, Molecular Probes/Invitrogen), and IRDye 800-labeled 
anti-rabbit IgG (1:3000, Rockland Immunochemicals, Gilbertsville, PA).  Membranes 
were washed and fluorescent signals measured directly on the Odyssey Infrared Imaging 
System (LI-COR).  Band density analysis was performed using Odyssey software (v2.1) 
supplied by the manufacturer.  Antibody specificities for the following have been 
previously established:  rabbit anti-pan NR1 (Fernandez-Monreal et al., 2004; Miyamoto 
et al., 2005; Offenhauser et al., 2006; Talbot et al., 2006; Li et al., 2007), mouse anti-NR1 
(Siegel et al., 1994; Siegel et al., 1995; Wood et al., 1995; Lack et al., 2005; Stepulak et 
al., 2005; Perez-Otano et al., 2006; Welch et al., 2007), rabbit anti-NR3A (Ishihama and 
Turman, 2006), rabbit anti-NR2A (Miyamoto et al., 2005; Yashiro et al., 2005), and goat 
anti-NR2B (May et al., 2004; Pawlak et al., 2005; Yashiro et al., 2005; Czaja et al., 
2006).  Mouse anti-NR3 antibody produces no band at the expected molecular weight 
(~130 kD) in NR3A knockout versus wild-type cortical homogenates (data not shown).  
Antibody signal intensities were collected from three separate experiments for each 
sample.  A standard curve of increasing protein amounts of pooled sample was 
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immunoblotted for each protein to ensure a linear relationship between increasing total 
protein amounts and density of the respective bands (data not shown). 
Data Collection and Statistical Analyses 
 
To assess mRNA levels for each human target gene, GUSB was used as the 
internal reference gene and relative quantities were obtained by the CT method using 
Sequence Detection Software (SDS v.2.2.2, Applied Biosystems).  Western blot 
experiments measured antibody signal intensities in postmortem tissue, interleaving 
control and experimental conditions where appropriate.  A pooled sample was run on 
each gel and the band density of each experimental sample was measured relative to this 
reference standard to permit inter-gel comparisons.  Samples were run in triplicate 
experiments, and individual antibody values for each sample were averaged. 
Developmental age group or diagnosis group means were calculated from 
individual averages.  Group means were normalized either to the mean level of 
expression for the maximally-expressing age group (developmental studies) or to the 
control group (schizophrenia and antipsychotic drug studies).   For multiple group 
comparisons, one-way analyses of variance (ANOVAs) were performed, followed by 
between-group comparisons with Tukey-Kramer tests.  Unpaired Student’s t-tests were 
used to compare diagnosis between schizophrenic subjects and normal controls with 
NMDAR proteins as variables.  Two-way ANOVAs were performed post hoc to probe 
interactions between diagnosis and sex.  All levels of significance represent two-tailed 
values.  Statistical analyses were conducted using Graphpad Instat (San Diego, CA) and 
SAS (Cary, NC).  Developmental brain tissues binned into seven groups based on age 
were not significantly different with regard to pH or sex; however, significant differences 
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were observed between the groups due to PMI (ANOVA, F(6,38)= 8.11, p < 0.0001) and 
storage time (ANOVA, F(6,38)= 8.08, p < 0.0001) (see Table 2.1).  Therefore, we included 
PMI and storage time in secondary ANCOVA analyses with these variables as covariates.  
While brain tissues from normal controls and schizophrenic patients had no significant 
differences between groups with regard to age, pH or PMI, a significant difference was 
detected between the groups due to storage time.  No secondary analyses were performed 
for the schizophrenia study. 
 
Results 
 
NR1 and NR3A, but not NR2A and NR2B, protein levels can be studied effectively in 
postmortem tissue 
 
A difficulty of studying human tissue is that protein degradation occurs during the 
postmortem interval (PMI) after death and prior to tissue preservation.  Therefore, it is 
necessary to assess how PMI affects antibodies’ recognition of target sites.  To test this, 
we used a mouse model to mimic the decay of human tissue under simulated morgue 
conditions (Jarskog et al., 2004).  Protein integrity was measured by immunoblotting of 
cortical homogenates run in triplicate (Figure 2.1).  Antibodies directed against NMDA 
receptor subunits NR3A (125kD), NR2A (165kD), and NR2B (170kD), as well as 
loading controls, -tubulin (55kD) and GAPDH (36kD), all detected single bands at the 
appropriate molecular weights, consistent with predicted sizes.  The double band for NR1 
(116kD) may be the result of splice variants, deglycosylation, or proteolytic cleavage 
products (Monyer et al., 1992; Brose et al., 1993; Sheng et al., 1994; Zukin and Bennett, 
1995; Luo et al., 1996). 
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Immunoblotting revealed that NR1 and NR3A proteins displayed modest and 
predictable decreases in band densities, with no main effects noted by ANOVA (NR1, 
n=4/group, F(2,9)=3.01, p=0.10; NR3A, n=4/group, F(2,9)=2.89, p=0.11).  Moderate 
protein degradation was also observed for the loading controls, although the decrease in 
-tubulin reached statistical significance (-tubulin, n=4/group, F(2,9)=6.27, p=0.02; 
GAPDH, n=2/group, F(2,3)=7.06, p=0.07).  Unlike NR1 and NR3A, however, degradation 
of both NR2A and NR2B subunits was substantial and progressive, with total decreases 
in signal intensities of 69% and 75%, respectively.  ANOVA demonstrated that there was 
a main effect of PMI on NR2A and NR2B levels (NR2A, n=4, F(2,9)=18.91, p<0.001; 
NR2B, n=4, F(2,9)=30.74, p<0.0001), and post hoc analyses revealed that protein levels 
were significantly reduced at both 12 and 24 hr PMI compared to baseline (PMI=0) 
values.  This effect of postmortem interval on NR2A and NR2B is consistent with the 
rapid proteolysis of NR2 subunits soon after death in human tissue (Wang et al., 2000), 
and is also consistent with difficulties in reliably measuring NR2A and NR2B levels in 
rhesus monkeys (O'Connor et al., 2006) and in human tissue (current study, data not 
shown).  For these reasons, we performed no further analyses of NR2A and NR2B in 
human tissue.  Furthermore, to minimize problems arising from studying tissue taken 
after a long PMI, we limited our analysis to tissue with a relatively low PMI (mean PMI 
~ 13 and 21 hours for the developmental and schizophrenia studies, respectively). 
Our mouse data indicate that NR1 and NR3A subunits exhibit relatively high 
postmortem stability (>65%) for at least 24 hours, suggesting that they are also likely to 
be more stable in human tissue than NR2 subunits.  Importantly, our pilot experiments 
demonstrated that in both mouse and human tissue, the NR1 and NR3A antibodies 
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recognized bands consistent with predicted sizes at 116kD and ~130kD, respectively.  
This indicates that these antibodies similarly recognize mouse and human NMDAR 
subunit homologues at their expected molecular weights.  Assuming the postmortem 
stability of these proteins is similar in mice and humans, our data indicate that the NR1 
and NR3A antibodies used in this study are appropriate to study these NMDAR subunits 
in human postmortem tissue.  
In addition to PMI, another important consideration in western blotting of 
postmortem tissue is accurate protein band measurement.  Typically, signal intensity for 
the protein of interest is measured relative to an in-lane reference, a loading control such 
as GAPDH or -tubulin.  However, as both of these common proteins varied 
considerably in their expression levels across development (data not shown), they were 
inappropriate for our studies.  To overcome this limitation, we instead standardized 
protein levels of each sample to a homogenate pool that was included on every gel as a 
reference (see Methods), and allowed for inter-gel comparisons.  Other studies have 
found similar methods to be reliable alternatives for quantification (Quinlan et al., 1999; 
Folkerth et al., 2004; Haynes et al., 2005; Murphy et al., 2005; Glantz et al., 2007; Salimi 
et al., 2008).   GAPDH and -tubulin normalizations were then used only for 
confirmatory analyses of adult samples in the schizophrenia study (Supplementary 
Figures S2.4 and S2.5), which had similar levels of these loading control proteins across 
groups.  Thus, unless otherwise noted, all analyses were performed on protein levels 
standardized to the pooled sample that was run on each gel.  Moreover, protein data from 
each sample was averaged from three independent western blotting experiments, as this 
further eliminated the possibility of loading errors. 
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Developmental expression of NR3A peaks in early childhood in human DLPFC 
 
Studies in rodents indicate that expression of the non-conventional NMDAR 
subunit, NR3A, is upregulated soon after birth, peaks during early postnatal life (around 
postnatal day 7; P7), then decreases through the subsequent weeks in many regions of the 
brain (Ciabarra et al., 1995; Sucher et al., 1995; Das et al., 1998; Sun et al., 1998; Al-
Hallaq et al., 2002; Sasaki et al., 2002; Wong et al., 2002; Ishihama and Turman, 2006; 
Perez-Otano et al., 2006).  We hypothesized that NR3A expression in humans is also 
upregulated early in development and downregulated in adolescence.  To test this, we 
determined NR3A transcript levels by quantitative RT-PCR of postmortem human tissue 
from individuals aged 18 wks gestation to 25 years (see Table 2.1 and Methods).  Our 
studies focused on the DLPFC, an area implicated in higher cognitive function, and in 
which NMDAR hypofunction has been hypothesized in the pathophysiology of 
schizophrenia. 
Consistent with previous rodent studies, we found highly regulated expression of 
NR3A during prenatal and postnatal cortical development for both mRNA and protein 
levels (Figure  2.2).  NR3A mRNA expression was shown to be significantly regulated 
across the various age groups (ANOVA:  F(6, 35) =8.60 , p<0.0001).  Post hoc analyses 
indicate that NR3A transcript levels are significantly reduced prenatally compared to the 
0-1 yr group (p<0.0001), the 1-5 yrs group (p<0.05), and the 11-15 yrs group (p<0.01).  
Furthermore we observed a statistically significant decline in NR3A from the peak 
expression of NR3A mRNA (0-1 yr group) compared to the 1-5 yrs group (p<0.02), the 
6-10 yrs group (p<0.001), the 11-15 yrs group (p<0.02), the 16-20 yrs group (p<0.01), 
and the 21-25 yrs group (p<0.0001).  These data demonstrate that NR3A transcription is 
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weak embryonically, increases dramatically in the first year of life, and then declines 
progressively into adulthood.  NR3A mRNA expression levels increased 10-fold from the 
fetal samples as compared to the age group with peak expression.  In a secondary 
analysis, we performed an ANCOVA covarying PMI and storage time across the 
different age groups (ANOVA:  F(6, 33) =6.84 , p<0.0001).  The results were largely 
consistent with the previous analysis run without covariates, as post hoc tests indicated 
that fetal tissue was significantly reduced compared to the same older age groups as 
described above (p<0.05).  Moreover, the peak expression of NR3A mRNA (0-1 yrs) was 
significantly greater than that at 16-20 yrs (p<0.02) and 21-25 yrs (p<0.01).  Unlike the 
primary analysis, peak expression compared to 1-5 yrs, 6-10 yrs, and 11-15 yrs age 
groups was not significant. 
Strikingly, developmental changes in NR3A protein abundance were qualitatively 
similar to that of NR3A mRNA levels.  After low prenatal expression, a sharp postnatal 
increase in band densities was followed by a progressive reduction in NR3A protein 
levels through childhood and adolescence (Figure 2.2).  A one-way ANOVA detected a 
significant effect of age on NR3A expression (F(6,38)=5.60, p<0.001).  Subsequent Tukey-
Kramer post hoc tests revealed that prenatal and young adult (ages 21-25 yrs) tissues 
expressed significantly less NR3A than infants aged 0-1 yr (p<0.001 and p<0.01, 
respectively).  Also, prenatal values differed significantly from age groups 1-5 and 6-10 
(both p<0.05).  The results of an ANCOVA covarying PMI and storage time across the 
different age groups (ANOVA:  F(6, 36) =4.72 , p<0.002) and post hoc tests were 
consistent with the previous analysis, indicating that even with PMI and storage time 
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taken into account, the developmental differences we observed were robust and still 
significant. 
To examine NMDAR expression changes in another relevant model system where 
postmortem protein decay was not a potential confound, we immunoblotted NMDAR 
subunit proteins in developing postnatal macaque temporal cortex (Supplementary 
Figure S2.1A). Postmortem frozen cortical brain tissue from 17 rhesus monkeys 
(Macaca mulatta) ages 3 months to 8 years were obtained from D.A. Lewis (University 
of Pittsburgh).  Although we were unable to acquire fetal macaque tissue,  our findings in 
monkeys show similar developmental changes as those observed in human postnatal 
NR3A protein expression (Figure 2.2), with high expression in infancy that tapers off 
into adulthood. 
 
NR1 levels are relatively high in the developing human DLPFC 
 
As the obligatory subunit of the NMDA-type ionotropic glutamate receptor 
(Monyer et al., 1992; Perez-Otano et al., 2001; Matsuda et al., 2003), NR1 serves as an 
accurate gauge of the total number of NMDARs.  Transcript and protein levels of NR1 
have been reported in various brain regions in humans (Zhong et al., 1995; Akbarian et 
al., 1996; Scherzer et al., 1998; Law et al., 2003; Clinton et al., 2006; Kristiansen et al., 
2006) and in rodents (Monyer et al., 1994; Laurie et al., 1997; Goebel and Poosch, 1999; 
Prybylowski and Wolfe, 2000; Sun et al., 2000; Ritter et al., 2002; Babb et al., 2005).  
However, to our knowledge, no study has examined NR1 expression over development in 
human prefrontal cortex. 
To determine the normal developmental profile of NR1 mRNA transcript and 
protein levels in the DLPFC, we again turned to quantitative RT-PCR and 
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immunoblotting (Figure 2.3).  NR1 mRNA expression was shown to be significantly 
regulated across the various ages (ANOVA:  F(6, 35) =8.26, p<0.0001).  As in the NR3A 
qPCR assays, there was a 10-fold increase in NR1 mRNA expression from prenatal to 
maximal postnatal levels.  Post hoc analyses revealed that in the group with the lowest 
mRNA content (fetal samples), NR1 was significantly (p<0.001) reduced compared to 
samples from the age group in which transcript levels were maximal, the 11-15 yrs group.  
Furthermore, samples from the 0-1 yr group (p<0.01), the 1-5 yrs group (p<0.05), and 
the 6-10 yrs group (p<0.05) also were significantly reduced compared to the 11-15 yrs 
group.  In a secondary analysis, we performed an ANCOVA covarying PMI and storage 
time across the binned age groups (ANOVA:  F(6, 33) =6.73 , p<0.0001).  As with the 
NR3A secondary analyses, these results were consistent with the primary analysis as well 
as subsequent post hoc analyses, suggesting that PMI and storage time were independent 
from the developmental differences we observed. 
Western blot analyses of frontal cortical homogenates prepared from the 
developmental samples demonstrate robust expression of NR1.  Consistent with NR1 
mRNA, protein levels are low prenatally and rise gradually to early adolescence and then 
decline modestly into adulthood (Figure 2.3).  Protein expression of NR1 was found to 
be significantly regulated across developmental groups (ANOVA:  F(6, 38)  =3.98 , 
p<0.005).  Post hoc tests indicate that the prenatal group was significantly (p<0.01) 
reduced compared to the 11-15 yrs group, and that there is a significant reduction 
(p<0.02) of NR1 protein levels when comparing the 11-15 yrs group to the 21-25 yrs 
group.  This reduction in adult tissue was not observed with NR1 mRNA, suggesting that 
protein expression may be regulated differently in maturity.  An ANCOVA covarying 
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PMI and storage time across the different age groups found that NR1 mRNA expression 
was significantly regulated across developmental groups (ANOVA:  F(6, 36)  =2.86, 
p<0.05).  However, post hoc tests revealed that, unlike the previous analysis, fetal tissue 
failed to differ significantly from the 11-15 yrs group.  The observed significant (p<0.01) 
decline in protein levels comparing the 11-15 yrs group to the 21-25 yrs group was 
maintained when including PMI and storage time as covariates. 
In a parallel study of cortical development, we probed fresh-frozen postmortem 
tissue from developing postnatal macaque cortex for NR1 protein (generous gift from 
D.A. Lewis, University of Pittsburgh) (Supplementary Figure S2.1B).  Although not 
statistically significant, developmental expression levels of NR1 in monkeys appeared 
similar to that in humans, with high levels exhibited until a drop during late puberty. 
Because NR1 is essential for all functional NMDARs (Monyer et al., 1992; Perez-
Otano et al., 2001), the ratio of NR3A to NR1 provides an estimate for the proportion of 
NR3A-containing receptors out of the total pool of NMDARs (Supplementary Figure 
S2.2).  By this measure, the NR3A/NR1 mRNA ratio was shown to be significantly 
regulated across the various age groups (ANOVA:  F(6, 35) =14.66, p<0.0001).  Post hoc 
analyses indicate that peak NR3A/NR1 ratio of transcript levels (0-1 year of age) were 
significantly different from all other age groups.  NR3A/NR1 levels are significantly 
reduced prenatally compared to the 0-1 yr group (p<0.0001).  Furthermore we observed a 
statistically significant decline in NR3A/NR1 ratio from peak expression (0-1 yr group) 
compared to the all other age groups (p<0.0001).  In a secondary analysis, we performed 
an ANCOVA with PMI and storage time as covariates across the different age groups 
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(ANOVA:  F(6, 33) =13.09, p<0.0001).  The results of this analysis were consistent with 
the previous analysis run without covariates. 
The ratio of NR3A/NR1 protein similarly changed over development 
(Supplementary Figure S2.2).  A one-way ANOVA detected a significant effect of age 
on NR3A/NR1 (F(6,38)=7.81, p<0.0001).  Subsequent Tukey-Kramer post hoc tests 
revealed that prenatal tissue had a significantly lower NR3A/NR1 ratio than infants aged 
0-1 yr and ages 1-5 (p<0.0001 and p<0.01, respectively).  Furthermore, the maximum 
ratio of NR3A/NR1 (0-1 yr) differed significantly from all other age groups (p<0.01) 
except 1-5 yrs.  From an ANCOVA covarying PMI and storage time across the different 
age groups (ANOVA:  F(6, 36) =7.27, p<0.0001) our results were largely consistent with 
the previous analysis, as well as subsequent post hoc analyses.  Of the differences we 
observed, fetal expression was no longer significantly different from the 1-5 yrs age 
group and maximal expression did not differ substantially from the 6-10 yrs age group.  
Overall, this impressive age-dependent regulation of NR3A/NR1 mRNA and protein 
levels underscores how vital the understanding of the ontogeny of these subunits will be 
to investigations of how their dysregulation contributes to neurodevelopmental disorders, 
such as schizophrenia or bipolar disorder (Mueller and Meador-Woodruff, 2004). 
 
NR1 and NR3A protein levels are unchanged in schizophrenic DLPFC 
 
A prominent theory of schizophrenia suggests that the disease may arise from 
NMDAR hypofunction in the prefrontal cortex (Javitt and Zukin, 1991; Tamminga, 1998; 
Weickert and Weinberger, 1998; Olney et al., 1999; Lewis and Levitt, 2002; Coyle et al., 
2003; Frankle et al., 2003).  However, studies examining NR1 levels in schizophrenia 
have found conflicting results (reviewed in (Kristiansen et al., 2007)), suggesting that 
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possible changes in NR1 levels need further evaluation.  To test whether protein 
expression of NR1 is abnormal in the schizophrenic DLPFC compared to tissue from 
comparison subjects (Table 2.2), we probed immunoblots of human tissue homogenates 
to measure NR1 protein (Figure 2.4).  A two-way ANOVA (diagnosis x sex) revealed no 
significant main effects on NR1 expression (diagnosis F1,31)=2.68, p=0.11; sex 
F(1,31)=0.08; p=0.78).  However, there was an interesting trend for an interaction between 
diagnosis and sex (F(1,31)=3.32, p=0.08) (Supplementary Figure S2.3), indicating that it 
might be worthwhile for future studies to investigate sex differences in NR1 expression 
in schizophrenic and control subjects.  
To our knowledge, the NR3A subunit has been evaluated for a role in 
schizophrenia in only one study, which demonstrated that NR3A mRNA levels are 
significantly increased by 32% within subregions of the DLPFC in schizophrenic patients 
(Mueller and Meador-Woodruff, 2004).  We hypothesized that schizophrenia could arise 
in part because of a failure of NR3A to downregulate during development.  Because 
NR3A suppresses calcium entry and NMDAR-mediated currents, higher than normal 
NR3A levels would be expected to cause NMDAR hypofunction.  Thus, we sought to 
determine whether NR3A levels were increased at the protein level in the DLPFC of the 
schizophrenic brain (Figure 2.4).  Contrary to our hypothesis, there was no main effect of 
diagnosis by a two-way ANOVA (F(1,31)=0.53, p=0.47), indicating that NR3A levels are 
similar in control and schizophrenic DLPFC.  However, there was a significant main 
effect of sex (F(1,31)=4.21, p<0.05) (Supplementary Fig. S3), suggesting that NR3A 
expression in the DLPFC is lower in females compared to males.  Storage time and PMI 
were not statistically controlled because no significant differences were observed 
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between men and women regarding these variables.  Although these findings are 
intriguing, limited tissue availability precluded our ability to further explore the possible 
gender-related regulation of NR3A.  To demonstrate that the lack of effect of NR1 and 
NR3A on schizophrenia was not a consequence of our standardization procedure, we also 
show similar results by standardizing band densities to loading controls, -tubulin and 
GAPDH (see Supplementary Figures S2.4 and S2.5). 
 
Antipsychotic drugs fail to alter NMDAR subunit expression 
 
Antipsychotic drugs are standard treatments for schizophrenic patients, primarily 
producing direct antagonistic effects on the dopamine and serotonin systems.  For 
example, haloperidol, a typical antipsychotic, is a potent dopamine D2-like receptor 
antagonist, whereas clozapine, an atypical antipsychotic, blocks not only D2 but also 
serotonin receptors.  Many drugs also interact directly with the glutamate system, binding 
to NMDARs (Ilyin et al., 1996; Gallagher et al., 1998) and affecting NMDAR expression 
and activity (Ossowska et al., 1999; Leveque et al., 2000; Ossowska et al., 2000; Schmitt 
et al., 2003; Bressan et al., 2005; O'Connor et al., 2006).  It was therefore important that 
we examine how antipsychotics affect the expression of NMDAR subunits. 
To evaluate the possibility that differences in NMDAR subunits between controls 
and schizophrenics might have been “normalized” by antipsychotic drug usage, we 
measured NMDAR subunit proteins in frontal cortical tissue from sub-chronic drug-
treated rats (Jarskog et al., 2007) (Figure 2.5).  Adult rats were injected for four weeks 
with saline, haloperidol, or clozapine, and immunoblotting was used to establish protein 
levels from cortical homogenates.  In our study, the drug treatments failed to modify 
NMDAR subunit levels, as indicated by ANOVA (Figure 2.5; 0.29< F(2,32)<1.16, p>0.32 
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for all subunits), suggesting that antipsychotic treatments are unlikely to have affected 
NR1 and NR3A protein levels observed in schizophrenic patients. 
 
Discussion 
 
To our knowledge, this report provides the first evidence, in any region of the 
human brain, for age-dependent differences in NMDAR expression spanning the range 
from gestation to early adulthood.  We performed quantitative analyses of NMDAR 
subunit mRNA and protein in postmortem human brain sections from the DLPFC.  
Specifically, we demonstrate (1) robust developmental regulation of NR3A and moderate 
developmental regulation of NR1, (2) close associations in abundance of NR3A and NR1 
transcript and protein levels, and (3) strong parallels to previous findings in developing 
cortex in other mammalian systems.  Our results show that NR3A levels are low 
prenatally, surge after birth, and then decrease progressively into adulthood.  These data 
indicate that NR3A serves a prominent role in the development of the prefrontal cortex 
soon after birth, and its role is likely less prominent prenatally and in adulthood. In 
contrast, NR1 levels rise from prenatal levels and vary only modestly over development, 
supporting a lifelong importance of NMDAR-dependent functions, including many forms 
of learning and memory.  The defined expression patterns of these particular subunits will 
increase our understanding of NMDAR-mediated processes during ontogeny, will aid 
studies of NMDAR dysfunction, and will guide the rational design of subunit-specific 
NMDAR pharmacotherapies for neurological disorders. 
 
Importance of age-dependent changes in NMDAR subunits to normal human 
development 
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NMDAR subunits exhibit remarkable heterogeneity of expression.  The 
significance of this molecular diversity is poorly understood in humans, in part due to a 
lack of knowledge of how these subunits change during development.  Compared to the 
rich literature describing developmental regulation of NMDAR subunits in animal 
models, human studies have been largely limited to investigations at the mRNA level 
(Law et al., 2003).  Studies measuring mRNA must be interpreted cautiously because 
protein and mRNA levels are not always well correlated (Luo et al., 1996; Philpot et al., 
2001b).  Thus, we felt it essential to accurately describe both NMDAR mRNA and 
protein levels in the human brain.  By using quantitative RT-PCR (Mimmack et al., 2004) 
and infrared immunoblot imaging, we obtained highly sensitive detection of mRNA and 
protein levels from postmortem tissues.  Additionally, the samples were binned into 
developmental age groups based on models of cortical development, which was a 
hypothesis-driven measure to enable us to overlay the data onto findings from prior 
investigations (Glantz et al., 2007; Salimi et al., 2008). 
While NR1 is obligatory for NMDAR function, the specific properties of 
NMDARs are shaped by the combination of NR1 with NR2 and/or NR3 subunits.  NR3A 
is the most recently described NMDAR subunit, and consequently its influence on 
NMDAR properties is less well-defined compared to the NR2 subunits.  However, 
interest in this unique subunit has grown recently with exciting observations that it acts in 
a novel, dominant-negative manner to reduce calcium influx and the unitary conductance 
of NMDAR currents (Ciabarra et al., 1995; Sucher et al., 1995; Perez-Otano et al., 2001; 
Sasaki et al., 2002; Matsuda et al., 2003), thereby suppressing NMDAR function.  Here 
we show that in human prefrontal cortex NR3A levels peak during early childhood and 
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then decrease into adulthood.  Animal studies have established a similar developmental 
pattern of NR3A expression (Ciabarra et al., 1995; Sucher et al., 1995; Das et al., 1998; 
Sun et al., 1998; Al-Hallaq et al., 2002; Sasaki et al., 2002; Wong et al., 2002; Ishihama 
and Turman, 2006; Perez-Otano et al., 2006), suggesting that this might be a general 
feature of mammalian brain development. 
What functions might high levels of NR3A have during early development?  
Based on in vitro and in vivo studies in animal models, at least six non-mutually 
exclusive possibilities exist for the function of NR3A during DLPFC development.  (1) 
Given that genetic deletion of NR3A in mice increases spine density (Das et al., 1998), 
NR3A may regulate the formation or loss of dendritic spines, the major sites of excitatory 
synapses.  Indeed, massive spinogenesis and synaptogenesis in infancy and early 
childhood, as well as synapse elimination in adolescence, have been demonstrated in both 
human (Huttenlocher, 1979; Bourgeois et al., 1994; Huttenlocher and Dabholkar, 1997; 
de Graaf-Peters and Hadders-Algra, 2006; Glantz et al., 2007) and non-human primate 
prefrontal cortex (Rakic et al., 1986; Bourgeois et al., 1994; Anderson et al., 1995; 
Gonzalez-Burgos et al., 2007).  (2) Because NR3A limits NMDAR-mediated calcium 
entry and its expression is elevated during a period of intense programmed cell death, 
NR3A is positioned to actively influence apoptosis by attenuating calcium-mediated 
excitotoxicity (Lipton and Nakanishi, 1999).  On the other hand, since NMDAR 
antagonism can also lead to cell death (Ikonomidou et al., 1999), excessive NR3A levels 
could actually promote apoptosis.  Thus, the relative balance of NR3A expression might 
serve to control which cells are targeted for cell death versus survival.  (3) Calcium is a 
critical mediator of both long-term depression and potentiation, which are thought to be 
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mechanistic substrates for learning and memory (Malenka and Bear, 2004).  NR3A-
dependent control of calcium entry would be expected to dramatically shape the 
properties of NMDAR-mediated plasticity, which could be revealed in future studies 
through mutant mice that either lack or overexpress NR3A (Das et al., 1998; Sucher et 
al., 2003; Brody et al., 2005).  (4) Exciting new data demonstrate that NR3A-containing 
receptors appear to undergo rapid endocytosis that is regulated in an activity-dependent 
manner by PACSIN1/syndapin1 (Perez-Otano et al., 2006).  Thus, NR3A may be 
important for clearing immature synaptic NMDARs so that they can be replaced by more 
mature receptors.  (5)  NR3A specifically forms a signaling complex with PP2A (Chan 
and Sucher, 2001), a phosphatase that can dephosphorylate NR1 subunits on serine 897.  
NR3A may indirectly modulate NMDAR function through this interaction, and thus 
provide bidirectional control of synaptic activity.  (6) Uniquely, NR3A-containing 
receptors lack strong blockade by magnesium at hyperpolarized potentials (Ciabarra et 
al., 1995; Sucher et al., 1995; Das et al., 1998; Al-Hallaq et al., 2002; Sasaki et al., 2002).  
Thus, while speculative, a novel role for NR3A-containing NMDARs during early life 
might be to support synaptic transmission at ‘silent synapses’ before there is an activity-
dependent mobilization of AMPA receptors to the synapse during maturation (Durand et 
al., 1996; Wu et al., 1996; Isaac et al., 1997; Rumpel et al., 1998; Zhu et al., 2000; Plitzko 
et al., 2001). 
The observation that expression levels of the essential NR1 subunit increase 
progressively from prenatal stages and remain relatively high throughout life is perhaps 
not surprising, as NMDAR function has been implicated in a variety of vital functions, 
including learning and memory, neuronal migration, synapse stabilization, pain 
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perception, and neuronal cell death (Komuro and Rakic, 1993) and reviewed in (Malenka 
and Nicoll, 1999; Cull-Candy and Leszkiewicz, 2004).  These data are consistent with 
that seen in other regions of the human brain (Law et al., 2003) and observations in 
animal models (Watanabe et al., 1992; Luo et al., 1996; Laurie et al., 1997; Chen et al., 
2000; Sans et al., 2000; Ritter et al., 2002; Awobuluyi et al., 2003; Ontl et al., 2004; 
Petralia et al., 2005).  NMDAR levels may also be particularly high in the DLPFC, as the 
prefrontal cortex may contain the highest concentration of NMDARs in the cortex 
(Scherzer et al., 1998).  Notably, NMDAR-mediated functions are apparently crucial 
even for embryonic life, because genetic deletion of NR1 in mice leads to neonatal 
lethality (Forrest et al., 1994). 
Whereas we observed clear developmental regulation of NR1 mRNA indicating a 
low prenatal level of expression compared to later developmental age groups, we 
observed a more modest increase in NR1 protein levels when comparing prenatal to 
maximum expression (11-15 yrs).  However, when we performed a secondary analysis 
using PMI and storage time as covariates, this difference in protein levels failed to reach 
significance.  Due to the modest developmental regulation of NR1 compared to other 
NMDAR subunits, such as NR3A, the detection of subtle differences in NR1 protein 
expression levels over development will require closer examination in future studies.  We 
largely observed similar trends in mRNA and protein expression in both NR3A and NR1.  
We did, however, observe one inconsistency.  Interestingly, whereas NR1 transcript 
levels remain high in adult prefrontal cortex, protein levels drop significantly.  Similar 
discrepancies between mRNA and protein levels have been noted and may result from 
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translational inefficiency, or increased rates of protein degradation (Awobuluyi et al., 
2003; VanDongen and VanDongen, 2004).   
The abundant NR1 protein levels observed during childhood are present during a 
period of extensive development of neuronal processes and formation of synaptic 
connections (Webb et al., 2001; de Graaf-Peters and Hadders-Algra, 2006).  Why does 
NMDAR expression peak around early adolescence in the DLPFC?  The elevated NR1 
levels may provide a molecular substrate for robust synaptic plasticity in cortical regions 
at this time.  The intriguing reductions in NR1 protein expression after puberty parallel 
the loss of synapses observed in human prefrontal cortex, and are consistent with a role 
for NMDARs in synaptic pruning or elimination in humans (Huttenlocher and Dabholkar, 
1997; Glantz et al., 2007) and in non-human primates (Bourgeois et al., 1994; Gonzalez-
Burgos et al., 2007).  Additionally, this might also be associated with critical period 
closure for many forms of NMDAR-mediated plasticity (Malenka and Bear, 2004).  
Currently little is known about NR3A in humans, but the high level of homology 
between human and rodent NR3A (93%) (Andersson et al., 2001; Eriksson et al., 2002) 
and the strong overall relationship between NMDAR subunit mRNA and protein levels 
found in this study suggest its function is likely similar between mammalian species.  To 
observe NMDAR developmental changes without the issues of postmortem degradation, 
we ran a parallel study in cortical tissue from rhesus macaque, a close genetic relative of 
humans (Gibbs et al., 2007), and found broad similarities to the human studies 
(Supplementary Figure S2.1).  Most importantly, the early peak in NR3A protein 
expression that tapers into maturity coincides with the developmental loss of NR3A in 
humans and rodents.  Thus, despite the unavoidable caveats associated with studying 
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human postmortem tissue, the similarities in the combined human transcript and protein 
data and monkey protein results produced from this study strengthen our conclusions and 
support the view that NMDAR subunits are similarly modified across development in 
rodents, non-human primates, and humans.  
We initially sought to characterize all the predominant subunits in postnatal 
cortex:  NR1, NR2A, NR2B, and NR3A (Watanabe et al., 1993; Monyer et al., 1994; 
Sheng et al., 1994; Stocca and Vicini, 1998).  Because all proteins are subject to decay 
after death, we first established our ability to quantify NMDAR subunit levels in 
postmortem tissue using immunoblotting (see Methods).  While > 65% of NR1 and 
NR3A remained intact up to a 24 hr PMI, less than 50% of the NR2A and NR2B levels 
could be detected.  This was consistent with our difficulty, and that of others, in reliably 
measuring NR2A and NR2B levels in human and non-human primate tissue (Wang et al., 
2000; O'Connor et al., 2006).  While we observed rapid decay of NR2A and NR2B with 
these particular antibodies (see Methods), protein degradation may differ among epitopes 
or different tissue preparation techniques.  As such, antibodies or approaches may exist 
that are better suited for detecting NR2A and NR2B levels in tissue with long PMIs (see 
(Murphy et al., 2005; Kristiansen et al., 2006).  Due to our difficulties in detecting NR2A 
and NR2B levels, we focused on NR1 and NR3A. 
 
Relevance of NR1 and NR3A expression to schizophrenia 
 
Because NMDAR hypofunction has been hypothesized to underlie some of the 
cognitive deficits observed in schizophrenia (Javitt and Zukin, 1991; Jentsch and Roth, 
1999; Olney et al., 1999; Lewis and Levitt, 2002; Coyle et al., 2003; Frankle et al., 2003), 
we asked whether this could be due to alterations in NMDAR subunit proteins within the 
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DLPFC.  Reports of subunit modifications in schizophrenia are largely conflicting 
(reviewed in (Kristiansen et al., 2007)).  Our data reach the same conclusions as 
Kristiansen and colleagues (Kristiansen et al., 2006), indicating that NR1 protein levels 
are unchanged in the schizophrenic brain.  Subtle changes in NR1 splice-variant 
expression (Prybylowski and Wolfe, 2000; Magnusson et al., 2005) might account for 
alterations of the subunit, but may not be detectable in our system.   
Recent data raised the intriguing possibility that NMDAR hypofunction in 
schizophrenia might arise from an aberrant increase in NR3A expression, as NR3A 
suppresses NMDAR function and NR3A mRNA transcript levels are significantly 
elevated in the DLPFC of schizophrenic patients (Mueller and Meador-Woodruff, 2004).  
In this same region where NR3A is overexpressed, spine densities are reduced in 
schizophrenic patients (Glantz and Lewis, 2000).  Because NR3A likely has a strong 
influence on limiting spine density (Das et al., 1998), a lack of the normal developmental 
downregulation of NR3A could result in significant reductions in spine numbers.  
Therefore, it is appealing to hypothesize that NR3A levels are elevated in schizophrenics, 
as this could explain both the NMDAR hypofunction and the reductions in dendritic 
spine density that have been observed. 
However, our data provide the first evidence that schizophrenia is not associated 
with a gross change in NR3A at the protein level within the DLPFC.  Given that NR3A 
expression is normally very low in the adult brain (this study), and that subregion- and 
lamina-specific differences in the expression of NR3A exist (Mueller and Meador-
Woodruff, 2004; Bendel et al., 2005; Mueller and Meador-Woodruff, 2005), we cannot 
rule out the possibility that there may be subtle or region-specific differences in NR3A 
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proteins that our methods were unable to detect.  A more selective analysis of synaptic 
membranes from different regions and/or laminae have the potential to reveal significant 
differences in receptor protein expression in the schizophrenic brain, if such differences 
exist.   
Even in the absence of differences in adult NR3A protein levels, other 
possibilities for NMDAR hypofunction involving NR3A may exist.  Genetic variants of 
NR3A could provide a molecular substrate for abnormal NR3A function (Gallinat et al., 
2007), particularly relevant for prefrontal information processing.  As schizophrenia is 
considered a neurodevelopmental disorder, a transient increase of NR3A during 
development could disturb the normal formation of cortical circuits, yet not be apparent 
in the adult brain (Lewis, 1997).  Because antipsychotic drugs can alter NMDAR subunit 
expression in a regional-specific manner (Fitzgerald et al., 1995; Hanaoka et al., 2003; 
Schmitt et al., 2003; O'Connor et al., 2006), we explored the possibility that drug 
treatments might account for the normal levels of NR3A and NR1 we found in 
schizophrenic patients.  After modeling the effects of sub-chronic clozapine and 
haloperidol exposure in rodent frontal cortex, we found that NMDAR subunit expression 
is unchanged, consistent with previous observations (Hanaoka et al., 2003).  Although we 
cannot preclude the possibility that different antipsychotic treatment regimens might alter 
NMDAR protein levels, our data suggest that normal NR1 and NR3A protein levels in 
the DLPFC of schizophrenic patients are unlikely to be consequences of antipsychotic 
treatments.  This suggests either that overall NMDAR hypofunction in schizophrenia is 
not related to widespread changes in NMDAR proteins or that such deviations fail to be 
maintained throughout life in this brain region.  We argue that the NMDAR hypofunction 
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observed in the disease is not maintained by gross differences in total NMDAR number 
or the proportion of NR3A-containing NMDARs, although there may be more subtle 
laminar or regional effects. 
In light of reports of gender influences in normal NMDAR expression, as well as 
in schizophrenia, we examined possible gender differences in NR1 and NR3A.  We 
observed marginal significance for sex-based differences suggesting that females have 
significantly less NR3A and a trend for less NR1 than their male counterparts.  The 
meaning of these results in human DLPFC is unknown.  However, there is a precedent 
for gender-specific differences in NR1 expression within other regions of the brain (Shi 
and Schlenker, 2002; Ontl et al., 2004), suggesting that NR1 levels are differentially 
regulated by sex hormones (Gazzaley et al., 1996; McEwen, 2002).  Like NR1, NR3A 
levels might also be regulated by sex hormones, such as estrogen.  Indeed, genetic 
deletion of NR3A impairs prepulse inhibition, a measure of sensorimotor gating, in male 
but not female mice (Brody et al., 2005).  This finding suggests that estrogen might 
normally downregulate NR3A levels, thus mirroring effects of genetic NR3A deletion in 
mice.  Such an interpretation would be consistent with our observation that NR3A, and 
possibly NR1, levels are lower in the DLPFC of females compared to males.  It might 
also explain the observation that there is a sex-specific difference in prepulse inhibition in 
normal human subjects (Swerdlow et al., 1993).  Interestingly, schizophrenics are known 
to exhibit deficits in prepulse inhibition to startle (reviewed in (Braff et al., 2001b)), 
suggesting a potential link between sex-specific NMDAR subunit expression and the 
schizophrenic condition.  While we stress the preliminary nature of these gender-related 
observations, the possibility for reduced expression of NR3A in females warrants more 
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intense scrutiny, as it could provide a biological basis to explain why female 
schizophrenic patients tend to manifest symptoms at a later age, are more responsive to 
medications, and exhibit less severe symptoms than males (Castle and Murray, 1991).  
While we attempted to carefully address the confounding factors that are inherent 
to all human postmortem studies, one of the main limitations to such investigations is the 
relatively small numbers of postmortem brain samples available.  However, even after 
considering such factors as PMI, pH, sex, ethnicity, and storage time on the quality of the 
mRNA and proteins studied, we still found significant developmental changes in 
NMDAR subunits, suggesting the increases and decreases in expression patterns are due 
to robust developmental regulation.  The observed statistical differences in 
developmental NMDAR subunit levels likely represent the most dramatic and consistent 
age-dependent differences in subunit levels.  Analyses of additional tissue might reveal 
more subtle developmental effects.  It is important to note that the current study 
represents the first developmental analysis of NMDA receptors in human cortex from 
gestation to adulthood.  Developmental studies in human brain of key regulatory systems 
– including glutamate – are needed to advance our understanding of normal brain 
development and provide insight into the pathophysiology of neurodevelopmental 
disorders such as schizophrenia. 
In summary, we report the developmental and schizophrenia profiles of NMDA 
receptor subunits, NR1 and NR3A, in human prefrontal cortex.  The data are consistent 
with lifelong functional roles for NR1 and a particularly important role during early 
human brain development for NR3A.  Our results also suggest that there are no gross 
differences in NR1 and NR3A protein levels between schizophrenic and control DLPFC.  
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Collectively, this study will be relevant in understanding subunit functions in key 
NMDAR-mediated processes of ontogeny, such as the formation and refinement of 
cortical circuits.  Additionally, these results contribute to understanding subunit roles in 
disorders of NMDAR dysfunction, such as the basis for NMDAR hypofunction in 
schizophrenia, as well as subtype-specific targeting in drug development. 
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Tables 2.1 and 2.2 
 
CHAPTER 3 
 
 
Modulation of excitatory synapse development by NR3A 
 
Abstract 
 
 The balance between synapse stabilization and elimination is highly sensitive to 
developmental changes in the complement of synaptic proteins.  The repertoire of 
synaptic proteins, specifically including glutamate receptors, ultimately determines 
whether synapses will be strengthened or weakened by plasticity mechanisms of long-
term potentiation and depression.  The molecular composition of NMDA-type glutamate 
receptors (NMDARs) changes over development, much of which is driven by sensory 
experience.  The transition from immature to mature NMDAR phenotypes in synapse 
maturation has been recognized, but the contributions of the NR3A subunit in this 
process have only begun to be considered.  Although removing endogenous NR3A 
accelerates synapse maturation and overproduction of NR3A limits synapse potentiation 
and stabilization, neither the subcellular localization of NR3A-containing receptors at 
peak expression levels, nor the consequences of their deletion has been rigorously 
established.  Using biochemical fractionation and quantitative immunoblotting, we have 
characterized the synaptic presence of NR3A and examined the distribution of a subset of 
proteins involved in synaptic maturation.  Our data support a model whereby NR3A 
negatively regulates the expression of proteins involved in excitatory neurotransmission, 
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synaptogenesis, and spine growth.  The developmental loss of NR3A may thus guide the 
maturation and stabilization of excitatory synapses. 
 
Introduction 
 Activation of the NMDA-type glutamate receptor (NMDAR) is crucial for 
synaptic strengthening and weakening (Malenka and Bear, 2004), which occur primarily 
in early brain development (Engert and Bonhoeffer, 1999; Matsuzaki et al., 2004).  
NMDARs are ionotropic channels that form through assembly of NR2 (A-D) and NR3 
(A-B) subunits with the obligatory NR1 dimer (Furukawa et al., 2005).   Most research in 
the mouse forebrain has concentrated on the canonical subtypes, NR2A and NR2B.  
Recent reports, however, have focused on how the inclusion of NR3 subunits reduces 
currents, and lowers both calcium permeability and sensitivity to magnesium block 
(Ciabarra et al., 1995; Sucher et al., 1995; Nishi et al., 2001; Matsuda et al., 2002), 
resulting in suppression of NMDAR activity.   
 Developing synapses undergo alterations in glutamate receptor content.  In early 
postnatal life, synaptic activity and sensory experience induce modifications in the PSD 
by promoting the transition between ‘immature’ and ‘mature’ forms of NMDARs (NR2B 
to NR2A), accompanied by the synaptic incorporation of AMPA receptors (AMPARs).  
These changes regulate the stabilization of NMDARs in the PSD, the subsequent decline 
in plasticity of the synapse, and the associated spine growth with maturation (Perez-
Otano and Ehlers, 2004).   
Removal/replacement of juvenile NR3A-containing NMDARs is involved in 
experience-driven synapse maturation (Roberts et al., 2009), yet the molecular 
mechanisms of this transient expression are unknown.  Aberrant synaptic changes in both 
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NR3A-null and NR3A-overexpressing mice suggest this subunit influences 
synaptogenesis.   NR3A knockout mice exhibit a striking increase in the number of 
dendritic spines on pyramidal neurons (Das et al., 1998), while NR3A-overexpressors 
have reduced synapse density (Roberts et al., 2009), indicating that NR3A plays a key 
role in spine and synapse formation and elimination (Henson et al.).   
To biochemically characterize the synaptic presence of NR3A and the effects that 
loss of NR3A has on forebrain content and intracellular distribution of other synapse-
associated proteins, we performed subcellular fractionation and quantitative immunoblot 
analyses in wild-type and NR3A KO mice.  Our subcellular characterization of NR3A 
provides evidence of its PSD-centric localization in early postnatal development that 
shifts to a more diffuse distribution in mature animals.  Accordingly, this thorough 
assessment of the levels of synaptic NR3A over development and the synaptic proteins 
associated with NR3A-containing NMDARs during peak expression will be crucial to 
our understanding of the biochemical events that accompany synapse maturation and 
elimination.  
 
Materials and Methods 
 
Animal use 
 Animal use in this study was approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill.  All rodents were 
maintained and sacrificed according to protocol guidelines. 
Tissue collection 
 Brains were removed from NR3A KO/WT mice aged postnatal (P) days 8, 16, 
and >40.  Forebrain tissue was rapidly dissected into dry ice and stored at -80°C until use. 
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Subcellular fractionation 
 One to three forebrains from each genotype, NR3A KO or WT, were pooled for 
each experiment. Biochemical fractions were prepared essentially as described (Yashiro 
et al., 2005).  Briefly, brains were dounce-homogenized in HEPES-buffered sucrose (4 
mM HEPES, 0.32 M sucrose, pH 7.4) and lysed in hypo-osmotic solution.  Synaptosomal 
fractions were isolated by density centrifugation (150,000 x g for 2 h) using a gradient 
consisting of 0.32, 0.8, 1.0, and 1.2 M sucrose in 4 mM HEPES, pH 7.4.  Synaptic 
plasma membrane fractions (SPM) were resuspended in 0.5% Triton X-100-containing 
buffer and centrifuged to obtain postsynaptic density (PSD) fractions.  Complete protease 
inhibitors (Roche Applied Science, Germany), and phosphatase inhibitor mixtures 1 and 
2 (Sigma-Aldrich, St Louis, MO) were added to all buffers.  Procedures were performed 
on ice and/or in a cold room and fractions were stored at -80°C.  Protein concentrations 
were determined by MicroBCA Assay (Pierce Chemical, Rockford, IL).  Fractions of 
interest in this study were comprised of the following cellular components:  PNS, whole 
homogenate, postnuclear supernatant; SPM, synaptic plasma membranes, complex of 
presynaptic active zone and postsynaptic densities with some extrasynaptic membranes 
attached; PSD, postsynaptic density isolated from detergent-extracted synaptic junctions. 
Quantitative immunoblotting 
 Increasing amounts (1 -15 μg) of total protein from each fraction were loaded in 
wells of 4-12% or 8% tris-glycine NuPage gels (Invitrogen), resolved by SDS-PAGE, 
and transferred to nitrocellulose membranes.  Blotting (Bio-Rad) and Odyssey system 
imaging and quantitation (LI-COR) were carried out following manufacturers’ protocols.  
The following antibodies were used at optimized concentrations: goat anti-NR1 (SC1467, 
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0.01μg/ml, Santa Cruz Biotechnology), rabbit anti-NR3A (07-356, 2μg/ml, Millipore), 
mouse anti-PSD-95 (MAB1596, 1μg/ml, Chemicon) mouse anti-synaptophysin (S-5768, 
0.5μg/ml, Sigma-Aldrich), mouse anti- tubulin (MAB 3408, 10μg/ml, Chemicon), 
Alexa Fluor 680-labeled anti-goat IgG (#A21084, Invitrogen), Alexa Fluor 680-labeled 
anti-mouse IgG (#A21058, Invitrogen), and IRDye 800-labeled anti-rabbit IgG (#611-
732-127, Rockland Immunochemicals). All immunoblots were repeated at least once with 
similar results. 
Data Analysis 
 Calculations of signal intensity per microgram protein were determined from 
multiple wells on each gel for each target antigen and then averaged across multiple gels.  
Fraction means per genotype were then either presented as immunoreactive units/μg 
protein or normalized to mean control values and expressed as % of control or % of 
maximum ± SEM.  Statistical evaluations were performed using two-tailed student’s t-
tests and significance placed at p < 0.05.  For multiple group comparisons, one-way 
analyses of variance (ANOVAs) were performed, followed by between-group 
comparisons with Tukey-Kramer tests.  Statistical analyses were conducted using 
Graphpad Instat (San Diego, CA). 
 
Results 
 
 We used biochemical fractionation and quantitative immunoblotting to 
characterize the subcellular localization of NR3A and to analyze how the presence or 
absence of NR3A alters synaptic protein expression over development in the mouse 
forebrain. 
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Biochemical enrichment of synaptic proteins by subcellular fractionation 
 We performed subcellular fractionation to selectively enrich forebrain 
homogenates for synaptic complexes and to isolate purified PSDs (Figure 3.1a).  This 
was then followed by immunoblot analysis of fractions containing cellular molecules of 
interest.  To demonstrate the quality of the biochemical enrichments from the whole 
homogenate fraction (PNS, postnatal supernatant), each preparation was assessed by 
immunoblotting for changes in specific markers: absence of membrane proteins (e.g. 
glutamate receptors) in the cytosolic fraction; absence of presynaptic protein, 
synaptophysin, in the PSD; absence of postsynaptic density protein, PSD-95, from the 
Triton-soluble fraction; and progressive enrichment of NMDAR subunit, NR1, and PSD-
95 from the initial homogenate (PNS) to the PSD.  These indicators provide assessments 
of the relative purity of the isolated PSD fractions (Figure 3.1b).  Representative western 
blots show NR1, PSD-95, and synaptophysin expression with the amount of protein 
loaded in each lane.  Because the PSD fractions are so highly enriched, protein loading is 
a two-fold reduction over the previous fractions in order to avoid saturation and to be 
able to accurately see differences.  
 
Glutamate receptors in forebrain PSDs are developmentally regulated in a subunit-
specific manner 
For comparative purposes, we defined the developmental expression profiles of 
the predominant NMDAR and AMPAR subunits present in forebrain fractions from P8, 
P16, and young adult mice.  This not only provided a baseline to which we could directly 
compare the NR3A data, but also confirmed the reproducibility of this biochemical 
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fractionation protocol.  NR1 is required for the functional expression of all NMDARs 
(Monyer et al., 1992; Perez-Otano et al., 2001; Matsuda et al., 2003).  Our data show that 
NR1 levels are similar across development within each fraction (Figure 3.2b:  NR1, 
ANOVA: PNS, F(2,18) = 1.636, p = 0.2258; SPM, F(2,19) = 1.404, p = 0.2727; PSD, F(2,19) = 
0.3277, p = 0.7250), consistent with previous reports (Monyer et al., 1992; Henson et al., 
2008).  However, NR1 expression is most highly concentrated in PSDs at each age tested 
(Figure 3.2b: NR1 ANOVA: P8, F(2,23) = 74.691, p < 0.0001; P16, F(2,17) = 44.507, p < 
0.0001; Adult, F(2,16) = 29.234, p < 0.0001).  NR2B expression across development was 
similar to that of NR1, with levels abundant early postnatally and changing only modestly 
with age (Figure 3.2b:  NR2B, ANOVA: PNS, F(2,19) = 2.304, p = 0.1302; SPM, F(2,19) = 
2.167, p = 0.1021; PSD, F(2,19) = 1.046, p = 0.3730).  NR2B is also highly concentrated in 
PSDs (Figure 3.2b: NR2B ANOVA: P8, F(2,23) = 32.582, p < 0.0001; P16, F(2,17) = 
77.483, p < 0.0001; Adult, F(2,17) = 31.964, p < 0.0001).  In contrast, western blot 
analyses of forebrain fractions demonstrate that NR2A levels are very low during early 
development, and increase dramatically over the first several weeks of life.  The robust 
developmental increases in NR2A levels within each fraction, suggest this subunit is 
significantly regulated across developmental ages (Figure 3.2b:  NR2A, ANOVA: PNS, 
F(2,18) = 12.544, p = 0.0005; SPM, F(2,19) = 53.279, p < 0.0001; PSD, F(2,18) = 28.588, p < 
0.0001).  This developmental shift in subunit composition has been well-characterized, as 
it alters the ability of synapses to strengthen and weaken in response to electrical activity 
and neurotransmitter binding.  Ratios of NR2A/NR2B also increase with development in 
PSD fractions (Supplemental Figure 3.1a: NR2A/NR2B, ANOVA: PSD, F(2,18) = 
21.994, p < 0.0001).  This is likely due to the profound increase in NR2A-containing 
 83
receptors, rather than a decrease in NR2B subunits, resulting in the activity-dependent 
shortening of synaptic currents.  Fold-enrichment quantification shows that NR1, NR2A, 
and NR2B are all highly enriched in the synaptic compared to whole homogenate 
fractions (Figure 3.2b: NR1 ANOVA: P8, F(2,23) = 51.082, p < 0.0001; P16, F(2,17) = 
100.08, p < 0.0001; Adult, F(2,14) = 41.656, p < 0.0001; NR2A ANOVA: P8, F(2,22) = 
19.036, p < 0.0001; P16, F(2,14) = 14.218, p = 0.0007; Adult, F(2,17) = 29.004, p < 0.0001; 
NR2B ANOVA: P8, F(2,23) = 41.095, p < 0.0001; P16, F(2,17) = 21.855, p < 0.0001; Adult, 
F(2,17) = 19.139, p < 0.0001), undergoing 7- to 14-fold increases in protein levels.  The 
high concentration of these subunits at the postsynaptic density is consistent with 
previous reports, and is responsible for NMDAR function in synaptic plasticity.  
 
High levels of NR3A are associated with membrane fractions and concentrated in PSDs 
To begin to understand how NR3A affects synapse maturation and elimination, 
we first needed to know to which subcellular compartments NR3A is targeted in neurons 
at the peak of its expression.  Like the NR2 subunits, NR3A expression is 
developmentally regulated.  However, its profile is unique, being highly expressed in 
early postnatal life and downregulating sharply into adulthood in humans, monkeys, and 
rodents suggesting this is a common feature of brain development and that the function of 
NR3A is similar between mammalian species (Henson et al.).     
 We determined the subcellular localization of NR3A at P8 in mouse forebrain as 
being prominently expressed in most biochemical compartments, such as light membrane 
and synaptic plasma membrane fractions that include intracellular organelles (e.g. 
microsomes, endosomes, Golgi, endoplasmic reticulum), and synaptic junctions  (Figure 
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3.2a), consistent with previous data from juvenile/adult rats (Perez-Otano et al., 2006).  
The presence of NR3A in membrane fractions suggests that these receptors may be 
mobile, as has been suggested of NMDARs in general (Tovar and Westbrook, 2002).  
Because the subcellular distribution of NMDARs determines receptor properties, further 
probing by quantitative analysis revealed that during its peak of expression, NR3A levels 
are highest in PSD fractions compared to whole homogenate PNS fractions (total receptor 
protein) from which it was derived (Figure 3.2b, ANOVA: P8, F(2,23) = 9.000, p = 
0.0015; P16, F(2,16) = 2.682, p = 0.1033; Adult, F(2,15) = 3.662, p = 0.055).  This 
demonstrates that NR3A is enriched in PSD fractions at P8 only.  However, this 
enrichment is weak when compared to other NMDAR subunits (Figure 3.2c, ANOVA: 
F(3,30) = 17.818, p < 0.0001), which is consistent with previous data from juvenile rats 
(Perez-Otano et al., 2006).  The low level of PSD concentration suggests that NR3A-
containing receptors are less effectively targeted to the synapse.  This is expected given 
that NR3A has no PDZ-domain binding motifs in its C-terminus to permit stable 
anchoring to the PSD, like NR2 subunits (Eriksson et al., 2007b). 
 
Developmental loss of NR3A from glutamatergic postsynaptic densities 
To determine how the subcellular expression of NR3A changes over 
development, we quantified whole homogenate and synaptic fractions taken from P8, 
P16, and young adult mice and found that levels of NR3A decrease in all fractions with 
age (Figure 3.2b, ANOVA: PNS, F(2,17) = 16.09, p = 0.0002; SPM, F(2,19) = 5.341, p = 
0.0159; PSD, F(2,18) = 19.777, p < 0.0001).  To further explore this, we then compared the 
PSD levels of NR3A over development.  Quantification of the percent in protein fractions 
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confirmed there is a developmental loss of NR3A from the PSD (Figure 3.2d, P16% of 
maximum = 70.8±8.4, p < 0.05; Ad% of maximum = 32.9±3.1, p < 0.0001).  The fractionation 
process removes synaptic membranes and active zones from the insoluble PSDs (SPM  
PSD, see Figure 3.1a).  These data suggest the decline in postsynaptic NR3A levels is 
possibly a shifting of the balance of NR3A to the general synaptic plasma membranes 
fraction. These data indicate that NR3A-containing NMDARs undergo an age-related 
shift in their subcellular localization. Thus, this is consistent with the idea that NR3A 
moves from a synaptic to a peri-/extrasynaptic location with development.  These data 
suggest that NR3A has a synaptic role in early postnatal development that may serve to 
limit synaptic plasticity, but that role may change with age.  This is also in line with data 
showing early onset of LTP in the NR3A KO mouse, as well as decreased LTP and 
memory consolidation that are linked to the prolonged synaptic presence of NR3A in 
mutant mice (Roberts et al., 2009). By limiting synapse potentiation, NR3A may have 
effects on synapse size, strength, and long-term memory. 
 
Synapse maturation markers, NR1, NR2A and GluR1, are enhanced in young NR3A KOs 
 Our recent study (Roberts et al., 2009) showed that NMDAR subunit abundance 
in synaptic fractions is significantly increased in P8 NR3A knockouts, while total NR1 
expression is unchanged.  This suggests that the genetic deletion of NR3A enhances 
synaptic concentration, and that stabilization of NMDARs, one of the initial events 
driving synapse maturation, occurs earlier in the absence of NR3A.  We reasoned that if 
NR3A negatively regulates NR1 localization and numbers at synaptic junctions, other 
glutamate receptor subunits might also be involved.  For further examination by 
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subcellular fractionation of tissue both containing and lacking NR3A, we selected 
subunits that are predominantly expressed in developing mouse forebrain:  NR2A, 
NR2B, and GluR1.  Western blots using an anti-NR3A antibody revealed a band of the 
expected size, which was absent in controls.  
 Immunoblot analysis of synaptic membranes revealed that, like NR1 (Roberts et 
al., 2009) (Figure 3.3a, NR1% of control = 133.5 ± 12.3 , n = 9, p < 0.05), PSD levels of 
synapse maturation markers are enhanced in P8 NR3A KO compared to WT mice for 
NR2A (Figure 3.3a, NR2A% of control = 150.4 ± 16.3 , n = 7-8, p < 0.05) and 
GluR1(Figure 3.3a; GluR1% of control = 142.4 ± 12.9, n = 8, p < 0.05).  No differences 
were observed in total receptor protein (PNS fractions, data not shown).  Both NR2A and 
GluR1 expression levels are normally very low at this age (Figure 3.2b, NR2A% of maximum 
= 12.69 ± 2.02, and Supplemental Figures 3.1a, GluR1 % of maximum = 13.49 ± 1.95), and 
their increased levels in mutant PSDs indicate that the loss of NR3A promotes the early 
concentrations of both subunits.  These data also suggest that NR3A inhibits synaptic 
expression of AMPARs as well as NMDARs.  Because the NR2B subunit is also highly 
expressed in immature forebrains during the early postnatal period, we examined whether 
any changes occurred for NR2B subunit expression in the NR3A KO forebrain at 8, 16, 
and 40-55 days of age postnatal.  This effect of selective upregulation of NR1 and NR2A 
is specific to these subunits, because we observed no differences in NR2B levels 
(Supplemental Figure 3.2, NR2B% of control = 100.6 ± 9.3, n = 8-9, p < 0.05).  Altogether, 
these data suggest that increased spine density observed in the KO mice results from 
exuberant spinogenesis that is unrestrained in the absence of NR3A and the data support 
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the notion of NR3A as a negative regulator of glutamate receptor surface expression in 
the maturation and stabilization of excitatory synapses. 
 
Early onset of synaptic glutamate receptor concentration may be transient 
To investigate whether the nature of the precocious concentration of NMDARs in 
NR3A KO mice was transient or sustained, we next examined mice at P16 and P40-55, 
the period during and after which synapse refinements are normally completed.  
Interestingly, for NR1 levels we find no difference between KO and WT by P16 (Figure 
3.3b, % of control = 97.25 ± 8.78, n = 6, p = 0.8449), the time when endogenous NR3A 
levels are normally declining.  This phenotype was still evident in more mature mice 
(Figure 3.3c, % of control = 104.64 ± 14.7, n = 6, p = 0.8278), which would be 
consistent for a modulatory role of NR3A in the narrow temporal window of its intense 
expression.  However, although not statistically significant, NR2A and GluR1 expression 
still trended towards elevated levels in both P16 (Figure 3.3b, NR2A, % of control = 
129.83 ± 19.85, n = 6, p = 0.28; GluR1, % of control = 144.05 ± 19.38, n = 6, p = 0.08) 
and young adult mice (Figure 3.3c, NR2A, % of control = 134.43 ± 18.72, n = 6, p = 
0.13; GluR1, % of control = 130.93 ± 21.71, n = 6, p = 0.24), an observation that may 
result from the prolonged effects of dysregulated programming in the absence of NR3A.  
The remarkably similar phenotypes in NMDAR and AMPAR subunits in immature 
NR3A KOs, along with the strong presence of NR3A proteins in the developing but not 
adult rodent brain, support a model in which NR3A negatively regulates glutamate 
receptor expression during normal postnatal CNS development and helps to mediate 
developmental synapse elimination and maturation.  Additionally, the slow return of 
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NR2A and GluR1 to control expression levels may point to prolonged, unchecked 
potentiation that is normally restrained by NR3A-NMDARs.  Further experiments need 
to be conducted to address this issue of whether or not glutamate receptor proteins remain 
elevated in mature NR3A KOs or if they return to control levels. 
 
Discussion 
 Synapses in many CNS regions undergo significant remodeling during postnatal 
brain development, although the molecules responsible for the elimination of 
inappropriate synapses and the maintenance and strengthening of appropriate connections 
are still largely unknown.  In this study, we sought to understand how the NMDAR 
subunit, NR3A, influences excitatory synapse development by defining the subcellular 
localization of NR3A over development as well as the composition of proteins modulated 
by NR3A during synapse refinement. 
 NR3A-containing receptors in the rodent CNS are most abundant during the 
second postnatal week (Henson et al.).  Our fractionation data localized NR3A peak 
protein expression predominantly to excitatory PSDs.  We also demonstrated a loss of 
NR3A from PSDs over time, suggesting there is an age-dependent shift in the subcellular 
distribution of this subunit.  These data are consistent with the idea that NR3A is targeted 
to PSDs early in postnatal life, and it moves from a synaptic to a peri-/extrasynaptic 
location over time.  NR3A’s age-dependent translocation from immature detergent-
insoluble structures to other membrane regions would be in line with juvenile and adult 
rat data showing that (1) NR2 subunits were not preferentially localized in PSDs (Al-
Hallaq et al., 2007), and (2) NR3A-containing NMDARs showed a uniform distribution 
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of NR3A at the neuronal surface, reflecting its weak association with the PSD (Perez-
Otano et al., 2006).  Such a shift would be important for functional properties of the 
receptor because synaptic activation of NMDARs requires glutamate binding to receptors 
clustered in the PSD.  NMDAR activation outside the synaptic cleft requires an excess of 
glutamate diffusing from presynaptic release sites.  Typically this occurs in mature 
animals under conditions of high frequency stimulation, glutamate release from 
astrocytes, or impaired uptake by glutamate transporters (Kohr, 2006).  Only high affinity 
(e.g. glutamate-binding NR2-containing) NMDARs are able to detect such low levels of 
glutamate.  Presynaptic NMDARs also can be functionally activated by ambient 
glutamate (Larsen, unpublished observations), but it is highly unlikely this receptor 
subpopulation is involved as they are largely downregulated in adults (Corlew et al., 
2007).  Furthermore, it is possible that, given its profile of developmental decline, NR3A 
undergoes a developmental shift from presynaptic to postsynaptic expression 
mechanisms.  However, this scenario also is not likely because the changes in synaptic 
levels over time suggest NR3A is more abundant in synaptic plasma membranes (which 
include PSDs) than in PSDs alone.  Biochemical analysis of NR3A in the presynaptic 
active zone (Phillips et al., 2001) will be needed to resolve this issue.  
 The subunit composition and synaptic localization of NMDARs in the developing 
forebrain affect channel activity and downstream signaling pathways.  NMDAR subtypes 
are targeted to distinct synaptic or extrasynaptic sites through their interactions with 
intracellular binding partners, such as membrane-associated guanylate kinases 
(MAGUKs; e.g. PSD-95 and SAP102). All NR2 subunits contain PDZ binding domains, 
which are required for PSD attachment through the MAGUKs.  Specifically, NR2A-
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containing receptors are thought to be delivered to the developing synapse by a 
preferential association with the prototypical anchor, PSD-95, while NR2B subtypes are 
trafficked by SAP102 (Sans et al., 2000; van Zundert et al., 2004).  However, this PDZ 
binding sequence is conspicuously absent in NR3 subunits (Matsuda et al., 2002; 
Eriksson et al., 2007b), indicating that the synaptic attachment of NR3A-NMDARs 
would be critically dependent upon NR2A and/or NR2B.  PSD associations of NR3A 
may be involved in activity-dependent changes in the subcellular distribution of 
NMDARs, as the synaptic removal of NR3A is an activity-dependent process.  Recent 
findings have shown that the regulated targeting of NMDARs to nascent synapses drives 
the developmental increase in NR2A-containing NMDARs (Philpot et al., 2001a; Barria 
and Malinow, 2002; Bellone and Nicoll, 2007), and hence the ability of the synapse to 
mature.  The effects that MAGUK-NR2 interactions may have on regulating the 
targeting, anchoring, and stabilization of NR3A at synaptic sites are unknown. 
 Recent data (Roberts et al., 2009), and this study) show that the ablation of the 
NR3A subunit does not reduce, but enriches forebrain contents of other endogenous 
glutamate receptor subunits, NR1, NR2A, and GluR1.   This suggests that NR3A is not 
required for but is responsible for restricting their expression.  These subunit-specific 
effects did not extend to NR2B, which was unchanged, suggesting that the loss of NR3A 
does not induce any compensatory expression of NR2B.  Furthermore, overexpression of 
NR3A results in a decrease in spine density and limited LTP in hippocampal neurons, as 
well as restricted expression on small spines in WT mice.  The data clearly indicate that 
the function of NR3A is likely correlated with changes occurring at glutamatergic 
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synapses in this timeframe.  Importantly, the synaptic inclusion of NR3A negatively 
regulates NMDAR subunit-specific expression and AMPAR insertion. 
 In this study, postsynaptic NR1 exhibited higher than normal expression in the 
NR3A KO, but returned to control levels in the narrow temporal window of only several 
days, in the same timeframe when endogenous NR3A levels are normally declining.  
Total NR1 expression was unchanged, suggesting that synaptic concentration and 
stabilization of NMDARs, one of the initial events driving synapse maturation, also 
occurs earlier in the absence of NR3A.  Thus, lack of NR3A may cause a re-arrangement 
of subunits and premature stabilization of synapses.  Data showing increased spine 
density in the NR3A KO mice (Das et al., 1998) might then be a result of exuberant 
spinogenesis.   
 The moderate increase of postsynaptic NR2A and GluR1 levels in P16 and adult 
NR3A-null PSDs is not significant, although we do not know if the differences are due to 
variability among samples or insufficient sample numbers.  The data may reflect the loss 
of inhibitory mechanisms in the absence of NR3A, the relief of the brake in synaptic 
maturation.  Such a scenario would be the outcome if NR3A were responsible for 
delaying the stabilization of NMDARs and the insertion of AMPARs at the synapse.  
Moreover, the prolonged absence of NR3A would be expected to cause an increase in the 
fraction of mature synapses (NMDAR+/AMPAR+), along the lines of NR3A removal 
triggering the ‘unsilencing’ of synapses.  The early onsets of synaptic NMDAR currents 
and LTP in NR3A knockout mice (Roberts et al., 2009) are in agreement with this 
interpretation, although these differences are not maintained in P16 and adult mice.  In 
addition, increased spine densities noted in the NR3A KO also do not return to normal by 
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adulthood (Das et al., 1998).  However, whether or not the overexpression of NR2A and 
GluR1 remain elevated through adulthood in NR3A KOs will require further 
experiments.  Regarding the inclusive evidence that the synaptic accumulation of NR2A 
and GluR1 may continue past P16, we cannot rule out the possibility that the total NR1 
content was not  detected:  if a splice variant-specific change in NR1 subunits was 
precipitated by the loss of NR3A (Smothers and Woodward, 2009), the NR1 antibody we 
used (domain-specific for the C2 splice variant, NR1-C2) may not have bound the entire 
antigen available if synaptic NR1 at P16 comprised more than the C2 isoform (Zukin and 
Bennett, 1995).  The limitations of biochemical studies also necessitate additional 
experiments to elucidate the association between the detergent solubility of glutamate 
receptors and PSD scaffolding proteins during development.  These will then reveal how 
NR3A acts as a molecular brake by restricting the developmental onset of glutamate 
receptor expression, which effectively prevents premature stabilization of excitatory 
synapses. 
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CHAPTER 4 
 
 
Conclusions and Future Directions 
 
Summary of findings 
Despite the functional importance of NR3A, its biochemical characterization and 
regulation at the synaptic level are still largely unknown.  This study provides the first 
systematic characterization of the normal developmental profiles of NMDAR expression 
in maturation of the (1) mouse forebrain from early postnatal life to adulthood in the 
presence and absence of NR3A, and (2) human prefrontal cortex from mid-gestation to 
early adulthood.  We defined the subcellular localization of NR3A over development as 
well as the composition of proteins modulated by NR3A during synapse refinement. 
Furthermore, we provide the first evidence that schizophrenia is not associated with a 
gross change in NR3A at the protein level within the human DLPFC.  Overall, my work 
supports a model of NR3A preventing the premature stabilization and promoting the 
elimination of glutamatergic synapses. 
While several groups have reported various aspects of NR3A expression and 
distribution (Henson et al.), none have performed rigorous assessments of the subcellular 
localization of NR3A, especially at the peak of its expression, or the consequences of 
genetic ablation of NR3A.  We performed quantitative analyses of NMDAR subunit 
mRNA and protein in mouse forebrains and postmortem human brain cortex.  
Specifically, we demonstrated (1) robust developmental downregulation of NR3A, (2)
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humans and rodents undergo analogous downregulation of NR3A, (3) synaptic targeting 
of NR3A declines with age, and (4) lack of NR3A may cause a re-arrangement of 
synaptic glutamate receptors and inhibit expression of synapse maturation markers.  Our 
results show that NR3A serves a prominent role in the development of the CNS soon 
after birth, and its role is likely less important prenatally and in adulthood. 
 
Influence of NR3A subunits in the developing brain 
NR3A is expressed in the right place at the right time to regulate spine and 
synapse development.  It is unclear, however, if the influence of NR3A is to serve as a 
‘synaptic brake’ to limit synapse/spine formation or if it serves as a ‘synaptic marker’ to 
promote the elimination of spines. These two hypotheses are not mutually exclusive and 
NR3A may influence both processes (Figure 4.1). 
 
Synaptic brake hypothesis 
NR3A-containing receptors may act collectively as a synaptic brake.  One 
possibility is that at early stages, when their expression is highest, they limit synapse 
formation by raising the threshold required for synaptic activity to induce synaptic 
maturation.  Later in development, activity-dependent removal of NR3A by 
PACSIN1/syndapin1 (Perez-Otano et al., 2006) would relieve this brake and allow the 
replacement of immature synaptic NMDARs by mature subtypes that are more stably 
anchored to PSDs.  Synapse maturation would then proceed with the recruitment of other 
synaptic scaffolds and signaling complexes, and the subsequent changes in spine 
morphology. 
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Synaptic plasticity mechanisms, such as LTP and LTD, influence the formation 
and stabilization of synapses and spines (Yuste and Bonhoeffer, 2001) and are critically 
dependent upon Ca
2+
 entry via NMDARs (Lisman, 1989).  The dominant-negative effect 
of NR3A on current and Ca
2+
 flux has recently been shown to limit synaptic plasticity 
(Roberts et al., 2009), providing a mechanism for NR3A control of spine and synapse 
density.  It will be interesting to determine whether NR3A knockout mice display 
changes in synaptic plasticity that are causally related to the changes in spine formation, 
or vice versa.   
While Das and coworkers (1998) reported increased spine density and enlarged 
spines in the cortex of P19 NR3A knockout mice, Tong et al. (2008) did not observe a 
related increase in the frequency or amplitude of AMPAR mEPSC in the same brain 
region in P10-P13 mice.  However, the NMDAR/AMPAR ratio was enhanced, reflecting 
an increase in the NMDAR component.  This sequence of events makes it tempting to 
speculate that larger NMDAR currents early in development favor enhanced LTP and 
subsequent increases in spine density/size in NR3A-deficient mice.  If true, the early 
developmental presence of NR3A may serve as a synaptic brake to prevent the premature 
strengthening of synapses, and thus ensure a well-coordinated strengthening and 
stabilization of only appropriate synapses in response to experience.  Early release of this 
brake in NR3A-null mutants would lead to enhanced spine formation and maturation of 
inappropriate synapses. 
 
Synaptic elimination hypothesis 
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 Another hypothesis consistent with the phenotype of NR3A-null mice is that 
NR3A serves as a tag to label weak synapses for elimination.  In this scenario, 
coordinated or strong synaptic activity could drive NR3A out of the synapse, possibly via 
activity- and NMDAR-dependent synaptic removal of NR3A.  Synapses with weak or 
uncoordinated activity would retain NR3A and, hence, be targeted for elimination.  
NR3A may also facilitate the elimination of immature synapses by recruiting the 
machinery necessary to exclude NMDARs from synapses, one of the steps thought to 
underlie synapse elimination and spine loss, via its interaction with PACSIN1/syndapin1 
(Perez-Otano et al., 2006). 
Another possible link between NR3A and spine elimination was suggested by the 
discovery of a family of proteins termed “takusans” that are upregulated in NR3A-null 
mice and appear to influence the formation of dendritic spines (Tu et al., 2007).  
Overexpression of takusans enhances spine density, AMPAR expression, and PSD-95 
clustering.  Considering that the expression of takusans is reciprocally regulated in 
development when compared to NR3A subunits, NR3A may foster spine elimination by 
limiting the synaptic expression of takusan proteins.  No direct interaction between these 
proteins has been observed, and future studies will be needed to investigate any causal 
relationship between NR3A and takusan expression.  
 
NR3A in disease 
Schizophrenia 
A prominent theory is that impaired glutamatergic transmission contributes to the 
pathophysiology of schizophrenia (Olney and Farber, 1995), and several lines of 
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evidence invoke an important role of NMDAR hypofunction (Coyle et al., 2003; Olney et 
al., 1999; Tamminga, 1998; Tsai et al., 1998): (1) NMDAR antagonists, such as PCP, 
exacerbate symptoms in patients with schizophrenia and produce symptoms nearly 
indistinguishable from schizophrenia in normal individuals (Javitt and Zukin, 1991).  
Genetic or pharmacological downregulation of NMDAR function in rodents also triggers 
schizophrenic-related behaviors (Moghaddam and Jackson, 2003; Mohn et al., 1999). (2) 
NMDAR co-agonists, such as glycine and D-serine, can improve cognitive functioning 
and alleviate negative symptoms associated with schizophrenia (Goff et al., 1999; Goff et 
al., 1995; Heresco-Levy et al., 1996; Heresco-Levy et al., 1998; Javitt, 2002; Javitt et al., 
1994; Millan, 2005; Tsai et al., 1998).  (3) Many candidate schizophrenia genes influence 
NMDAR signaling and expression (Chowdari et al., 2002; Harrison and Weinberger, 
2005; Martucci et al., 2003; Moghaddam, 2003; Straub et al., 2002).  For example, 
neuregulin, the protein product of a major schizophrenia susceptibility gene, alters the 
surface expression of synaptic NMDARs (Gu et al., 2005; Ozaki et al., 1997; Stefansson 
et al., 2004).  (4) More recently, imaging studies have provided the first in vivo evidence 
for reduced NMDAR binding in medication-free schizophrenic patients (Pilowsky et al., 
2006).  
Although the mechanistic basis for NMDAR hypofunction in schizophrenia 
remains unknown, it could be caused by a change in NMDAR subunit composition.  To 
date there is little consensus on alterations in NMDAR subunits that might contribute to 
the NMDAR hypofunction observed in schizophrenia (Akbarian et al., 1996; Meador-
Woodruff and Healy, 2000; Moghaddam, 2003).  However, a recent study demonstrated 
that NR3A mRNA levels are increased within layer 5 in subregions of the dorsolateral 
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prefrontal cortex in schizophrenics (Mueller and Meador-Woodruff, 2004).  This finding 
raises the possibility that inappropriate expression of NR3A could exacerbate this 
subunit’s unique ability to suppress receptor activity, and underlie NMDAR 
hypofunction.  Consequences of aberrant expression would be predicted to have a larger 
impact in the mature brain, where NR3A is remarkably downregulated in most brain 
regions.  Four further observations support a role for elevated NR3A in schizophrenia:  
(1) Schizophrenic brains exhibit decreased phosphorylation of NR1 at serine 897, which 
can be reversed by antipsychotics (Emamian et al., 2004).  Because NR3A subunits form 
a signaling complex with PP2A, which can dephosphorylate serine 897, overexpression 
of NR3A could contribute to the reductions in NR1 phosphorylation in schizophrenia 
(Chan and Sucher, 2001).  (2) Alterations in NR3A levels impair prepulse inhibition 
(Brody et al., 2005), a measure of sensorimotor gating that is also impaired in many 
schizophrenia patients (Braff et al., 2001a).  (3) Spine density is decreased in the DLPFC 
of schizophrenia patients (Glantz and Lewis, 2000, 2001), a region where NR3A levels 
are elevated (Mueller and Meador-Woodruff, 2004), and elevated NR3A levels have been 
shown to decrease spine formation (Roberts et al., 2009). (4) Impaired working memory 
in schizophrenia could be explained by deficits in NMDAR function, potentially resulting 
from NR3A overexpression, in layer 5 pyramidal neurons in the DLPFC (Fellous and 
Sejnowski, 2003; Sanchez-Vives and McCormick, 2000; Sucher et al., 1995; Wong et al., 
2002).  Although it is now clear that NR3A levels are not changed in a wholesale manner 
in the schizophrenic DLPFC (Henson et al., 2008), the above data underscore a need to 
further examine regional changes in NR3A expression, protein interactions, and signaling 
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in schizophrenics and to evaluate if/how they contribute to the pathophysiology of 
schizophrenia.   
 
White matter injury 
The dogma that NMDARs are expressed only in neurons within the CNS has been 
overturned, and increasing evidence indicates not only that NMDARs are expressed in 
glia, but also that glial NMDARs contain the NR3A subunit (Paoletti and Neyton, 2007).  
Three recent studies highlighted the role of NMDARs in oligodendrocyte damage 
(Karadottir et al., 2005; Micu et al., 2006; Salter and Fern, 2005), reporting that 
oligodendrocytes and the myelin sheaths they form are damaged by excitotoxicity in a 
number of acute and chronic disorders, including ischemic stroke, cerebral palsy, 
traumatic neural injury, and multiple sclerosis (Matute, 2006; Matute et al., 2007) 
(Figure 4.2).  Both Ca
2+ 
entry and subsequent oligodendrocyte damage could be 
attenuated by NMDAR antagonists, indicating that white matter damage was caused at 
least in part by NMDAR activation (Karadottir et al., 2005; Micu et al., 2006; Salter and 
Fern, 2005).  These studies demonstrated that NMDAR currents in oligodendrocytes 
failed to show rectification at hyperpolarized potentials due to Mg
2+
 block, mimicking the 
behavior of NR3A- or NR2C-containing NMDARs.  This suggests that these NMDARs 
are positioned to respond to glutamate activation, even in the absence of strong 
depolarization.  Further, all three studies showed that NR3A levels are high in myelin.  
Despite the low Ca
2+
 permeability of NR3A-containing NMDARs, high levels of NR3A-
containing NMDARs and/or insufficient Ca
2+
 buffering might predispose 
oligodendrocytes to cell death mediated by elevations of glutamate associated with 
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ischemic stroke or other excitotoxic events.  If so, the development of NR3A-selective 
antagonists could be of therapeutic benefit for preventing white matter excitotoxic 
damage, with less severe adverse side effects than broad spectrum NMDAR antagonists.  
 
Diseases of neuronal excitotoxicity 
A large number of neurological disorders are associated with increased 
excitotoxicity, including Huntington’s disease (Fan and Raymond, 2007), Parkinson’s 
disease (Bonuccelli and Del Dotto, 2006), Alzheimer’s disease (Wenk, 2006), chronic 
alcohol exposure (Crews et al., 1998; Lovinger, 1993), and neuropathic pain (Dubner and 
Ruda, 1992).  Other disorders associated with excitotoxicity include acute brain injuries 
such as stroke (Martin et al., 1998), epilepsy (Fujikawa, 2005; Meldrum, 1993), and 
traumatic injury (Arundine and Tymianski, 2004).  Excessive activation of NMDARs is 
thought to contribute to excitotoxicity because the depolarization-dependent activation of 
Ca
2+
 entry mediated by NMDARs can more readily induce cell death compared to other 
forms of glutamatergic activation (Abdrachmanova et al., 2002; Choi, 1992; Rothman 
and Olney, 1995).  While excessive glutamate activity triggers NMDAR-mediated cell 
death in most of these acute and chronic disorders, disruption of cellular metabolic 
processes can also cause depolarization-induced activation of NMDARs by shifting ionic 
balances (Zeevalk and Nicklas, 1992).   
The proposed role of NMDAR-mediated excitotoxicity in neuronal disorders has 
fostered intense research into the therapeutic benefits of NMDAR antagonists, but most 
efforts have yielded disappointing results due to harmful side effects of the antagonists 
(Hoyte et al., 2004; Lipton, 2006).  Because NMDARs are crucial for so many neuronal 
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functions, including learning and memory (Bear, 1996), and because too little NMDAR 
activation can also lead to apoptotic cell death (Ikonomidou et al., 1999), successful 
blockade of NMDAR-mediated excitotoxicity must carefully attenuate NMDAR 
functions without eliminating them (Lipton, 2006).  NR3A provides an attractive target 
for accomplishing this subtle manipulation of NMDAR functions.  One intriguing idea is 
that overexpression of NR3A might attenuate NMDAR-mediated cell death by reducing 
Ca
2+
 permeability of existing NMDARs.  However, such an approach would have to 
carefully titrate the degree of NR3A overexpression, as apoptosis can also be triggered by 
a dramatic decrease in NMDAR currents (Lipton and Nakanishi, 1999). 
A neuroprotective role for NR3A has recently been explored further by Nakanishi 
and coworkers (2009), who used in vivo models of hypoxic-ischemic insults as well as 
retinal cultures to examine the effects of NR3A on cell death.  Using NR3A knockout and 
transgenic overexpressing mice, these authors have provided convincing evidence that 
ischemic-induced neuronal damage is extensive in the absence of NR3A, while the 
presence of NR3A reduces cell loss (Table 2).  Other recent observations support their 
findings, namely that retinal ganglion cells are relatively invulnerable to NMDAR-
mediated excitotoxicity in contrast to many other neuronal classes (Ullian et al., 2004), 
and only the retinal cell types with high NR3A content exhibit attenuated calcium 
responses to NMDA (Nakanishi et al., 2009; Sucher et al., 2003).  Consistent with the 
idea that NR3A might offer neuroprotective benefits, high levels of NR3A expression 
during early brain development might explain why excitotoxicity is not more prevalent at 
ages before the maturation of inhibitory circuitry.  Perhaps it is not a coincidence that 
NR3A levels diminish during development (Wong et al., 2002) as inhibition increases 
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(Coyle and Yamamura, 1976).  These tantalizing correlations raise the possibility that 
exogenous introduction of NR3A might be useful to treat a variety of neurological 
disorders by preventing inappropriate cell death without producing deleterious side 
effects. 
 
Mental retardations associated with improper dendritic spine development 
Dendritic spines are the major site for excitatory synaptic connections on neurons.  
Changes in their number, density, and/or shape have been implicated in a number of 
mental retardations including Fragile X, Rett, and Down syndromes (Carlisle and 
Kennedy, 2005; Chechlacz and Gleeson, 2003; Fiala et al., 2002; Irwin et al., 2000; 
Kaufmann and Moser, 2000; Newey et al., 2005), but the molecular basis for these spine 
abnormalities remains unknown.  Activation of NMDARs is required both for the 
bidirectional changes in synaptic strength thought to underlie learning and memory 
(Malenka and Bear, 2004) and for the activity-dependent growth or retraction of spines 
which may help encode enduring changes in synapses (Engert and Bonhoeffer, 1999; 
Maletic-Savatic et al., 1999; Nagerl et al., 2004).  Therefore, dysregulation of NMDARs 
might contribute to abnormalities in spine number or shape that could be prevented (or 
reverted) by normalizing NMDAR activity.  Even if NMDAR dysfunction did not play a 
causal role, modifying NMDAR function could potentially ameliorate conditions arising 
from abnormal spine development.  Indeed, one of the most striking phenotypes of mice 
lacking NR3A is an approximate three to five-fold increase in spine density (Das et al., 
1998).  Studies in mice that lack or overexpress NR3A should help elucidate links 
between spine abnormalities and deficits in synaptic plasticity and learning, and hence 
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evaluate if targeted and carefully titrated exogenous modulation of NR3A could be of 
therapeutic value in certain forms of mental retardation. 
 
Other links of NR3A to clinical issues 
  NR3A is likely involved in other neurological conditions, yet possible roles for 
NR3A may have gone unrecognized. NR3A was identified relatively recently, and, 
because of this, it was not incorporated into many tests, such as gene array analyses, that 
could have detected its involvement in disease.  In addition to the direct and indirect 
suggestions of NR3A involvement in neurological disorders mentioned above, we list 
here other possible links of NR3A to disease.  (1) Decreased NR3A mRNA and protein 
levels have been reported in patients with bipolar disorder (Mueller and Meador-
Woodruff, 2004).  (2) Chronic low-level lead exposure during development is associated 
with cognitive impairments in young children (Bellinger et al., 1991), and decreased 
levels of NR3A mRNA are reported in rodent hippocampus after lead exposure (Zhang et 
al., 2002). (3) Genetic analyses of NR3A in humans have identified a common missense 
variation (Val362Met) that is associated with a strikingly different prefrontal cortex 
activation during auditory target processing (Gallinat et al., 2007).   
While these are just a few additional examples of how NR3A might be involved 
in neurological disorders, the recognized involvement of NR3A is likely to increase as 
disease-related changes in NR3A expression levels, polymorphisms, or function are 
evaluated. The above studies also provide direct evidence for a functional role for NR3A 
in the adult human brain, and further support the idea that modulation of NR3A in 
humans might alter neurological functions.  Development of specific agonists and 
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antagonists of NR3A may thus be of therapeutic value for a variety of neurological 
disorders.  Intriguingly, exposure of rodents to weak magnetic fields alters NR3A mRNA 
levels, raising the possibility that there may even be non-invasive and non-
pharmacological means to modify NR3A levels in humans (Hirai and Yoneda, 2004). 
 
Future Directions 
 There are a number of intriguing outstanding issues raised by my published data 
and unpublished observations that can be addressed by future studies.  Below I briefly 
outline several of these issues and propose methods to address them. 
 
Role of NR3A in synapse elimination 
 The localization of NR3A-containing NMDARs at the synapse needs to be fully 
elucidated.  However, imaging studies of molecular interactions at the synapse have 
historically been limited by the fact that synapses are incredibly small.  Conventional 
light microscopy methods are unable to magnify individual synapses to a high enough 
level of axial resolution to accurately distinguish these structures and their morphological 
features.   Array tomography is a powerful imaging technique that significantly improves 
the spatial resolution of closely apposed synaptic proteins over confocal microscopy 
(Micheva and Smith, 2007) and allows multiple comparisons in a single experiment with 
repeated probing of antibodies. I propose that array tomography might offer an approach 
to gain insights into the precise anatomical localization of NR3A-containing NMDARs, 
and how these receptors are positioned relative to other synaptic proteins.  NR3A-
containing NMDARs are thought to be preferentially expressed on small and excluded 
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from large synapses (Roberts et al., 2009).  However, whether or not NR3A-expressing 
spines are specifically eliminated remains unknown.  The three-dimensional renderings 
produced by array tomography would make it possible to clearly discern changes in 
NR3A-lacking vs. NR3A-containing synapses and thus to address the issue of a role for 
NR3A in regulating synapse elimination.  
 
Confirmation of NR1/NR3 excitatory glycine receptors in vivo 
 Subunit composition defines the functional properties of NMDARs.  
Conventional NR2-containing NMDARs are activated by glutamate, while NR1/NR3A 
receptors are thought to bind glycine alone.  The high glycine affinity of these receptors 
(Nilsson et al., 2007a; Yao and Mayer, 2006) suggests that they would be occupied at 
physiological concentrations of glycine in vivo, which may serve to keep neurons in a 
physiologically depolarized state.  However, convincing evidence of the NR1/NR3A 
diheteromeric combination is lacking.   Two methods, electrophysiological recordings 
and immunoprecipitation, would provide the complementary confirmation necessary to 
resolve this issue.   NR3A-containing receptors in slice recordings would be isolated by 
pharmacological blockade.  This is not a trivial experiment, because not only AMPARs, 
but also specific NR2 subunits would need to be blocked.  If an NR3A-specific 
electrophysiological signature was detected, the subunit composition of NR3A-NMDARs 
could then be determined by sequential co-immunoprecipitation on whole brain 
homogenates to examine specifically whether NR3A co-assembles with NR1 subunits in 
the absence of NR2.  It is possible that the assembly of functional NR1/NR3 receptors is 
NR1 splice variant-specific (Smothers and Woodward, 2009).  After immunodepleting 
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NR2-containing NMDARs with an NR2 antibody cocktail, the remaining NMDARs 
would be immunoprecipitated with anti-NR1 antibody and blotted for NR3A.  Detection 
of NR3A after this would confirm that these non-conventional glycine receptors exist in 
vivo and open up a field of research devoted to describing their functional roles. 
 
Sensory experience, critical period, and NR3A 
 The PACSIN1-mediated removal of NR3A is activity-dependent; however, 
whether or not NR3A expression is dependent upon sensory experience has not been 
reported.  Using a model of visual deprivation, I conducted pilot experiments with WT 
mice reared in darkness.  The harvested tissue was analyzed biochemically for changes in 
synaptic NR3A.  I found that dark-rearing increased NR3A abundance in PSD fractions, 
suggesting that NR3A expression may be experience-dependent. Moreover, the 
downregulation of NR3A expression occurs in parallel with onset of the critical period in 
the visual cortex (Berardi et al., 2000), suggesting that NR3A’s role as a molecular brake 
in synapse maturation may extend to the refinement of sensory modalities.  These issues 
could be addressed by combining techniques of visual deprivation, electrophysiology and 
biochemical fractionation 
 
Effects of the NR3A-PP2A association on NMDAR activity 
 Hypofunction of the NMDA receptor is thought to be associated with 
schizophrenia.  Elevated levels of NR3A could produce a form of NMDAR 
hypofunction.  Schizophrenic brains have decreased phosphorylation of NR1 at serine 
residue 897, and this can be reversed by antipsychotic medications (Emamian et al., 
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2004). PP2A is a phosphatase that can dephosphorylate serine 897 on NR1 subunits, and 
because NR3A forms a signaling complex with PP2A, overexpression of NR3A could 
contribute to the changes of NR1 phosphorylation observed in schizophrenia (Chan and 
Sucher, 2001; Ma and Sucher, 2004).  Additionally, PACSIN1 removes NR3A from 
synapses in an activity-dependent manner, using the same C-terminal binding site as 
PP2A (Ma and Sucher, 2004; Perez-Otano et al., 2006).  PP2A normally binds NR3A and 
releases this bond upon NMDAR activation, thereby making available the binding site for 
PACSIN1.  While these correlations are intriguing, there are no reports examining the 
possible links between these molecules and synaptic activity.  Li et al. (Li et al., 2009) 
reported the generation of phophomutant mice at Ser897-NR1.  The combination of these 
NR1 and NR3A mutant mice would provide the tools to parse the signaling roles of NR1, 
NR3A, PACSIN1 and PP2A.   
 
NR3A regulation of myelination 
 Until now, gene expression profiling has not been used to identify genes that are 
differentially expressed at the peak of NR3A expression (P8 in mice).  We recently 
analyzed data from DNA microarrays to define subsets of genes that are reciprocally 
regulated (overrepresented in the absence of NR3A and underrepresented under 
conditions of NR3A overproduction) in NR3A mutant mice.  Surprisingly, our analysis 
revealed that myelination genes are prominently represented in the NR3A transcriptome.  
The tantalizing correlation between NR3A loss and the enrichment of these myelin-
associated genes is intriguing, because NR3A levels are high in myelin and NR3A has 
been implicated in white matter injury (Karadottir et al., 2005; Salter and Fern, 2005; 
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Micu et al., 2006).  These intriguing microarray results could be verified in future 
experiments by quantitative immunoblotting of proteins in biochemical fractions and 
possibly immuno-EM.  We expect that, consistent with their increased transcript levels in 
the NR3A KO microarrays, protein expression will also be elevated for proteolipid 
protein 1 (Plp), myelin basic protein (MBP), contactin-associated protein 1 (CASPR1), 
CNPase, and neurofascin (Nfasc). 
 
Presynaptic vesicle genes are upregulated in NR3A-null forebrains 
To date, little is known about the mechanisms by which presynaptic NMDARs 
regulate neuronal signaling in the CNS.  New evidence suggests NR3A may promote 
neurotransmitter release in synaptic transmission by tonically activating presynaptic 
NMDARs in the absence of depolarization (Larsen, unpublished observations).  The 
activity of NR3A-lacking NMDARs is tightly regulated by voltage-sensitivity and the 
developmental decline of presynaptic NMDAR function parallels the downregulation of 
NR3A.  In light of these findings, we were intrigued to find in DNA microarrays that 
several synaptic genes that are involved in the activation of vesicular fusion, and the 
release of neurotransmitter into the synaptic cleft are upregulated in NR3A-null mice.  It 
is possible that NR3A may be involved in presynaptic mechanisms by regulating the 
vesicle release machinery. NR3A may restrict the expression of these proteins until axon 
terminals are prepared for the increased activity demands at the synapse during circuit 
refinement.  Future studies are needed to validate the transcript data by examining the 
protein localization in subcellular compartments of the synaptic vesicle membrane 
proteins, synaptophysin (Syp), VAMP2 (vesicle-associated membrane protein 
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2)/synaptobrevin, SNAP-25, and complexin (Cpx1).  As all of these molecules are 
intimately involved in synaptic vesicle release (Sudhof, 2004), their overproduction in 
mutant mice suggests NR3A signaling is tightly linked to their function.  Specific 
fractionation techniques that isolate the presynapse (Phillips et al., 2001) would be useful 
in determining the precise subcellular distribution of these proteins and parsing the 
presynaptic mechanisms of release in NR3A KO mice. 
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APPENDIX I 
 
Developmental loss of presynaptic NMDARs parallels the downregulation of NR3A 
 The notion of presynaptic NMDARs as important modulators of synaptic 
strengthening and weakening in developmental plasticity has been largely ignored, but is 
rapidly gaining momentum. NR3A-containing receptors uniquely act to suppress 
NMDAR-mediated neurotransmission, possibly regulating the synaptic pruning that 
occurs during this critical developmental timeframe. Because NR3A may play a 
significant role in the tonic release of glutamate by presynaptic NMDARs (Larsen et al., 
Nat Neuro, in revision), an exciting possibility is that this regulation may occur through 
the expression of NR3A in presynaptic as opposed to postsynaptic NMDA receptors. 
 We asked if shifts in subunit composition could explain why the tonic function of 
preNMDARs during early life is lost later in development (by ~P20 in mouse visual 
cortex)(Corlew et al., 2007). To determine which subunits have a developmental profile 
matching that of functional preNMDARs, we quantified protein expression of candidate 
NMDAR subunits during development of mouse primary visual cortex (V1). Similar to 
the obligatory NR1 subunit, protein levels of NR2A and NR2B subunits increase with 
age in V1 (Figure A.1). NR2C (Karavanova et al., 2007) and NR3B (Nishi et al., 2001) 
are not expressed at the right time and regions to contribute to preNMDAR functions in 
the neocortex. NR2D expression levels did not show a significant developmental change; 
furthermore, NR2D levels are extremely low in V1 compared to brainstem (Figure A.2). 
In contrast, the expression of NR3A is high early in development and declines 
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dramatically after the third postnatal week (ANOVA group effect, p < 0.001, Figure 
A.1), matching previous observations (Wong et al., 2002; Roberts et al., 2009). Thus, the 
developmental decrease in NR3A expression matches the loss of preNMDAR functions 
observed by the third postnatal week (Corlew et al., 2007). This raises the possibility that 
the NR3A subunit might underlie the tonic activity of preNMDARs. 
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